

Day	Time	Session	No.	Name	FINAL TITLE
Fr	08:00	Antibacterials - Clinical Aspects - Part I	434	Basnet	Erythromycin: Magic Bullet for Sore Throat and its Consequences in Children
			875	Ashraf	Randomized controlled clinical trial of day-care based and hospitalized management of severe childhood pneumonia by injection ceftriaxone in Dhaka, Bangladesh
			910	Cizmarevic	Management of deep space neck abscesses. Five year experience
			726	Müllhaupt	Alveolar echinococcosis: The impact of chemotherapy and surgery on survival
Fr	08:00	Antineoplastic agents - New targets & compounds - Part I	142	Schatten	Breast and Prostate tumor cell destruction by Salmonella with preferential targeting of mitochondria
			194	Diaconu	TARGETING MUTATED JANUS KINASES IN MYELOPROLIFERATIVE NEOPLASMS DRUG DISCOVERY
			1494	Misevic	Selective stimulation of human natural killer cells proliferation by novel fucosylated acidic glycan drugs: possible therapeutic use for treating cancer and viral/retroviral infections
Fr	08:00	Antibacterials - Discovery - New methods of chemical significance	1128	Primeau	The Discovery of New Scaffold Antibacterial Agents
			1246	Chang	Neomycin, Kanamycin and Pyranmycin: Synthesis, Antibacterial Activity and New Applications
			941	Demirbas	Synthesis of Some New 1,3,4-Thiadiazol-2-ylmethyl-1,2,4-Triazole Derivatives and Investigation of Their Antimicrobial Activities
			264	Moorthy	Synthesis, in silico ADME-Tox study and Antimicrobial Evaluation of some small Molecules
			108	Chmielewski	AN ENTRY TO CLAVAMS FROM CHIRAL VINYL ETHERS AND CHLOROSULFONYL ISOCYANATE
			1190	De Luca	A Simple Microwave-assisted Synthesis of Sulfonamides directly from Sulfonic Acids
Fr	08:00	Antibacterials - New antibiotic and antineoplastic compounds from nature - Part I	143	von Nussbaum	Chemical Postevolution of Antibacterial Natural Products
			838	Berdy	Natural Products (NP) - Microbial Metabolites (MM) - Antibiotics (AB): History, Facts and Problems, Where Now ?
			1420	Hoshina	Dioxin like compounds for anti-infective agents of know as its degrading enzyme from Geobacillus midousuji thermophile
			522	Egwuatu	Disinfectant effect of Garcinia kola extract on Staph. Aureus
			594	Boboye	Drug Potential of Nigerian MedicinE Related Plants: A SURVEY

Day	Time	Session	No.	Name	FINAL TITLE
Fr	08:00	Antibacterials - New compounds and mechanisms - focusing on tuberculosis and delivery	86	Makino	Pulmonary Drug Delivery System for Efficient Treatment of Tuberculosis
			1266	Tastan Bishop	Mode of Action of a Naphthoquinone on Tuberculosis
			362	Ishikawa	Discovery of a Novel Anti-MRSA Agent TAK-599 (Ceftaroline Fosamil): An N-Phosphono Water-Soluble Prodrug for Intravenous Injection
			463	Drulis-Kawa	Interactions of liposomal vesicles with bacterial cells and antimicrobial activity of liposomal antibiotics
			1009	Andries	A diarylquinoline targeting the energy supply of M. tuberculosis has the Potential to change the TB treatment paradigm
Fr	08:00	Antibacterials - Resistance, surveillance, and guidelines	497	Randhawa	CIPROFLOXACIN RESISTANCE PROFILE IN KLEBSIELLA PNEUMONIAE ISOLATES DURING 2002-2007 IN PAEDIATRIC SEPTICAEMIC CASES OF A TERTIARY CARE HOSPITAL IN INDIA
			193	Rodrigues	Antimicrobial Prophylaxis in Surgery and Emergence of Super bugs: Dilemma in Developing Countries
			823	Scott	Bacterial tetracycline resistance: prevalence, evolution and dissemination of genes
			430	Dar-Odeh	Dentistry and Antibiotic Resistance: The Need to Set Guidelines and Improve Prescribing Practices
			858	Ilina	Molecular investigation of drug resistant Neisseria gonorrhoeae clinical isolates
			422	Prasad	Clinical Importance of Antimicrobial Resistance
			337	Sonnenfeld	Drug Resistance in Surgical Infection

Day	Time	Session	No.	Name	FINAL TITLE
Fr	08:00	Antineoplastic agents - Effectiveness and resistance in patients - Part I	1244	Driedger	Molecular guidance systems for nuclear-tipped magic bullets?: Clinical experiences in thyroid cancer treatment using recombinant TSH to activate the target
			503	Nadali	Multidrug Resistance Inhibition in Acute Myeloblastic leukemia by Antisense Oligonucleotide
			1148	Lingwood	Verotoxin (Shiga toxin) binding to its receptor glycolipid, globotriaosyl ceramide, provides a new antineoplastic tool and physiologically-based approaches to tumour cell drug resistance
			1391	Kulcsar	Experimental Evidence for Killing the Resistant Cells and Raising the Efficacy of Cytostatics by a New Anticancer Drug Candidate (Culevit Infusion) Developed on the Basis of the Passive Antitumor Defence System
			1077 1269	Chun Bilensoy	The urokinase system is a natural inducer of cancer cell drug resistance SAFE AND EFFECTIVE DELIVERY OF PACLITAXEL THROUGH AMPHIPHILIC BETA-CYCLODEXTRIN NANOPARTICLES
Fr	08:00	Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part I	1176	Moller	Development of SERCA Inhibitors Targeted towards Prostate Cancer Cells.
			652	Wu	The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
			699	Liu	Monitor of Chemosensitivity by Bcl-2 Transcript Kinetics in Acute Myeloid Leukemias
			322	Sánchez-Harguindey	PROTON TRANSPORT INHIBITORS (PTI) AS SELECTIVE ANTICANCER AGENTS
Fr	10:15	Antineoplastic agents - Tyrosine Kinase Inhibitors - Part I	859	Brünnert	Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562
			276	Ren	Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma, present status and application in China
			854	Ullrich	The critical role of IL-15 trans-presentation in the antitumor effects mediated by the combination therapy with Imatinib and IL-2

Day	Time	Session	No.	Name	FINAL TITLE
Fr	10:15	Antivirals - Mechanisms and development of antivirals - Part I	156	Menne	Antiviral effect of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate, administered orally alone and in combination, to woodchucks with chronic woodchuck hepatitis virus infection.
			351	Nikolaeva-Glomb	The Potential of Oxoglaucine, a New Antiviral Compound, to Inhibit Enterovirus Replication When Applied Alone or in Combination
			663	Komarov	Nitric oxide and zidovudine potentiate oxidative response of stimulated macrophages
			1754	Schröer	Non-steroidal Anti-inflammatory Drugs; a Potential New Way to Treat Human Cytomegalovirus (HCMV) Disease
Fr	10:15	Biomarkers and their applications	346	Marrer	Success story of the first regulatory approval of safety biomarkers, Part I: From identification to biological qualification
			665	Yamaguxhi	Noninvasively Evaluation on Human Stress Using Salivary Biomarker
			987	STYCZYNSKI	Strategic Role of Prednisolone, Vincristine and Asparaginase in Pediatric Leukemia as a Paradigm of Success in Oncology: Individualized Tumor Response Testing and Microarray Analysis
			249	Ayrapetyan	Cell Hydration as a Universal and Extra-sensitive Biomarker for Determination of the Functional State of the Organism
			783	Feng	Pivotal Evaluation of the Accuracy of a Diagnostic Biomarker: the PRoBE Study Design
			721	Mohorovic	Methemoglobin as the Biomarker of Environmental Oxidants and Precursor of Adverse Effects of Oxidative Sress on Mother and Fetus - Reasons for its Early Detection and Therapy
Fr	10:15	Blood-brain barrier - History and most recent finding - Part I	476	Hammarlund-Udenaes	The blood-brain barrier and its magic transporters – a pharmacokinetic perspective on how to optimize drug delivery to the brain
			625	Dreifuss	Circumventing the blood-brain-barrier. Soviet attempts during World War 2
Fr	10:15	Pharmaceutics - Drug delivery - Part I	492	Daly	Cyclotides, ultrastable peptide frameworks for magic bullet drug delivery
			817	Martins Lopes	Optimize a therapeutic with NSAIDs: intelligent design for delivery systems
			992	Severin	Targeted delivery of cytotoxic drugs by means of protein vectors

Day	Time	Session	No.	Name	FINAL TITLE
Fr	10:15	Masspektrometry in pharmaceutics and biochemistry	1541	Hopfgartner	Masspektrometry in pharmaceutics and biochemistry
Fr	10:15	Treatment of diseases with involvement of the immune system - Part I	360	Kmonickova	Novel Generation of Antivirotics: Combination of Antimetabolic and Immunostimulatory Modes of Action
			1183	Gladstone	High-dose cyclophosphamide is active in immune-mediated illnesses
			1252	Grygorczuk	Expression of Fas on human T lymphocytes under stimulation with <i>Borrelia burgdorferi</i> sensu lato.
			1363	Kalavi	Novel Immuno - potency Drugs
			7	Luk	Prevention of Inflammatory Leukocyte Adhesions for Treatments in Acute Sepsis Condition by Anti-CD18 sFv Single-Chain Antibody
			1175	Daftarian	Genetic immunization for the induction of humoral and cellular immune responses; a water in oil liposome-based in comparison with in vivo electroporation.
			144	Ebringer	Rheumatoid arthritis, Proteus and "magic bullets"
Fr	10:15	Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part I	460	Galabov	Perspective Chemotherapeutic Combination to Combat Flu
			110	Van Bambeke	One target, two bullets : from erythromycin to telithromycin, what makes the difference ?
			1364	McArthur	The use of DNA based therapies to restore clinical efficacy of antibiotics
Fr	10:15	Antibacterials - Resistance in gram positives	127	Lemaire	Magic activity of beta-lactam antibiotics against intracellular Methicillin-Resistant <i>S. aureus</i> (MRSA) : role of acidic pH.
			1247	Munsch-Alatossava	Antibiotic Resistance Of Psychrotrophs Spoiling Raw Milk
			365	Benabdellah	Susceptibilities of rickettsiae to antimicrobials
			491	Bathaie	Application of Saffron and Its Ingredients as a Known Pharmacological Herb from Ancient Times and the Mechanisms of Their Action

Day	Time	Session	No.	Name	FINAL TITLE
Fr	10:15	Antibacterials - Molecular microbiology	1248	Ehrlich	Prediction of species-specific targets for the development of STAMPs based on analyses of bacterial species-level supragenomes
			1245	Hu	Development of species-specific STAMPs (specific targeted antimicrobial peptide) that target and kill only <i>Streptococcus pneumoniae</i> within a polymicrobial community
			576	Grasemann	Augmenting endogenous nitric oxide production to kill multiresistant <i>P. aeruginosa</i> in cystic fibrosis lung disease.
			109	Marquez	Can We Make Eucaryotic Cells Resistant to Antibiotics? Correlation between Multidrug Resistance-associated Protein (Mrp) Efflux Pump Expression and Fluoroquinolones Accumulation in J774 Macrophages
			690	Mouithys-Mickalad	The unexpected hidden face of the Cephalosporin Antibiotic Ceftazidime: From biological to chemical and physical activities against oxidant species produced by phagocytes
Fr	10:15	Antineoplastic agents - New strategies and new compounds- Part I	455	Aboul-Fadl	Selenium Derivatives as Cancer Preventive Agents
			895	Hofmann	Heterocyclic hydrazones induce radical formation and dissipation of mitochondrial membrane potential
			234	Alakhov	Retargeting anticancer drugs to drug resistant cancers by using polymer Biotransport technology. Clinical proof of the concept
Fr	10:15	Treatment of severe diseases	1749	Briegel	Low-dose steroids in critically ill patients: Who should be treated and when?
			1758	Baumgart	Inhaled H ₂ S for suspended animation in anesthetized and ventilated mice
			1687	Simon	H ₂ S-induced suspended animation during porcine aortic occlusion-induced ischemia reperfusion injury
			1761	Wilhelm	Red blood cell omega-3 fatty acids and the risk of ventricular arrhythmias in patients with heart failure

Day	Time	Session	No.	Name	FINAL TITLE
Fr	13:15	Antineoplastic agents - Compounds and approaches - Part I	1020	De Kroon	The High Cytotoxicity of Cisplatin Nanocapsules in Ovarian Carcinoma Cells Depends on Uptake by Caveolae-Mediated Endocytosis
			870	Kondo	Experimental approach for growth inhibition of human malignancies by the highly efficient anti-tumor peptide delivery system
			250	MINGOMATAJ	Enigmatic eosinophil as magic bullet: Eosinophil-induced prognosis improvement of solid tumors could be enabled by their vesicle-mediated barrier permeability induction
			983	Koyama	Vitamin A and D Derivatives; Potential MAGIC BULLETS with Antithrombotic and Antineoplastic Applications
			694	Pryme	The potential of orally presented mistletoe lectins in cancer therapy
			614	Ogasawara	Green tea polyphenol, EGCG, prevents tumor lung metastasis in mice through enhancing anti-tumor immunity.
			557	Hsu	Anti-neoplastic properties of tea catechins are associated with pro-differentiation caspase 14 gene expression: implementation for novel therapies
Fr	13:15	Antineoplastic agents - Approaches to optimize therapy - Part I	37	Rodriguez-Antona	CYTOCHROME P450 DEPENDENT DRUG RESPONSE IN ONCOLOGY
			1022	Anilanmert	The Chemical Interaction of the Anticancer Drugs Irinotecan-HCl and Epirubicin-HCl in the Same Infusion Solution
			1381	Pereira Lopes	The differential dose-dependence for pro-angiogenic and cytotoxic effects of new anticancer plant agent within different nanocarrier formulations.
			724	Kitamura	KIT-deficient mouse and KIT-targeted drug
Fr	13:15	Antiparasitic compounds - Therapeutic approaches	1095	Francischetti	[Approaches against Malaria - final title not yet available]
			1116	Taoufiq	Fasudil: the new "magic bullet" to thwart Malaria mortality?
			297	Sullivan	Plasmodium Heme Crystallization: Methylene Blue to the Quinolines
			439	Bestaoui	Mediterranean spotted fever(MSF) in Oran (Algeria)

Day	Time	Session	No.	Name	FINAL TITLE
Fr	13:15	Pharmaceutics - Experimental and computational approaches - Part I	305	Zhang	New Development of Drug Solubilization
			241	Cerda	ELECTROCHEMICAL BEHAVIOR OF FLAVONOIDS IN THE PRESENCE OF METAL IONS
			435	Cukrowski	Fundamental Understanding on Interactions of Bisphosphonates with Bone (by Use of Different Techniques, Including Computational Modelling)
Fr	13:15	Antivirals - General issues and their solutions - Part I	882	Pathak	Differential roles of physiological and physicochemical parameters on low and variable bioavailability of Saquinavir- hurdles of effective drug treatment
			1076	Berencsi	Possible Consequences of Transplacental Transfer of Viruses in Healthy Pregnants
			661	Pungpo	Elucidating Inhibitor-enzyme Interaction of Highly Potent Non-nucleoside Reverse Transcriptase Inhibitors Active Against Wild-type and Mutant HIV-1 Strains: Computer-aided Molecular Design Approaches
			775	Fialho	HIV/AIDS and Malarial/Toxoplasmosis Co-Infections: a Magic Bullet Approach to Drug Development
			1389	Cholewinska	Bulletprooves to Abacavir-related Hypersensitivity Reaction in HIV-infected Population
			620	Davis	New neutralizing monoclonal antibodies from HIV-1 subtype C and CRF02_AG infected people
Fr	13:15	Blood brain barrier physiology and diseases - Part I	167	Focosi	5-HT2a antagonists as a new treatment for JCV-associated progressive multifocal leukoencephalopathy
			942	Lagarde	Blood choline phospholipids as preferential sources of docosahexaenoic acid to the brain
			378	Harling-Berg	Hierarchy of Immune Responses behind the Blood-Brain-Barrier (BBB) in the Normal Brain: Implications for the development of CNS Diseases and Treatment
			396	Nag	Pathogenesis of Blood-Brain Barrier Breakdown Following Brain Injury: Windows for Therapeutic Intervention

Day	Time	Session	No.	Name	FINAL TITLE
Fr	13:15	Antineoplastic agents - New mechanisms & compounds - Part I	979	Auerbach	The role of endothelial cell heterogeneity in the search for anti-angiogenic agents
			1241	Yeung	Antineoplastic effects of an aurora B kinase inhibitor against breast cancer
			1756	Witzens-Harig	Rituximab Maintenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – First results of a multicenter prospective randomised Phase II study
			1165	David-Cordonnier	Molecular mechanism of action and cellular consequences of the DNA minor groove alkylating agent S23906-1
Fr	13:15	CNS - Pharmacological options in disease of the central nervous system - Part I	1375	Borrell	Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors
			437	Tapia-Perez	The clinical role of the statins in surgical neurosciences
			295	Gallagher	Multiple mechanisms of action and pharmacological activities of valproate'
			818	Mendelson	Are the Substituted Phenethylamines Magic Bullets? Benefits and Harms of Amphetamines and Related Compounds
			739	Gupta	Cholinesterase Inhibitors and NMDA Receptor Antagonists in Alzheimer's Disease and Pesticide Poisoning
			443	Clauss	Zolpidem after brain Damage
			827	Birnbaumer	Structure and Functions of the ubiquitous TRPC Channels: Targets in need of magic bullets
Fr	13:15	Recombinant Proteins - a new class of Magic Bullets- Part I	1369	Gaziola de la Torre	Synergy between structural stability and DNA-binding controls the antibody production in EPC/DOTAP/DOPE vesicles and DOTAP/DOPE lipoplexes
			947	Endo	Discovery of Malaria Vaccine Candidates – Application of the HT Cell-Free Protein Production System Born of the Study on Ricin Toxin
			1138	Huang	The Impact of Inflammatory Responses on Taste Bud Cell Turnover and Function
			1347	Von Wettstein	Wheat and barley for celiac patients by molecular silencing of the immunogenic endosperm proteins
Fr	13:15	Antibacterials - Adverse events and mechanisms of toxicity - Part I	10000	Tulkens	Aminoglycosides as a paradigm of multidisciplinary approach to drug toxicity
			458	Vakharia	Prevention of hepatotoxicity in patients undergoing anti tuberculosis treatment: A novel integrative approach.

Day	Time	Session	No.	Name	FINAL TITLE
Fr	13:15	Vaccines - Development, production and manufacturing - Part I	1215	Lalosevic	Selection of Cell Culture Substrates for Human Viral Vaccines
			1417	Garcon	Adjuvant Systems for vaccines targeting unmet needs: from concept to clinical evidence
			746	Gedvilaite	Recombinant virus-like particles and their application for vaccine development and diagnostics
			572	Lobo	Inhibition of HIV-1 through an Innate Humoral Mechanism – a Potential for Vaccine Development
			1779	Harrer	Therapeutic Vaccination Followed By Antiretroviral Therapy Interruption (TI): Results From A Single Blind, Randomized, Controlled, Multicenter Phase II Study With An MVA-Nef Vaccine In HIV-1 Infected Patients
Fr	13:15	Vaccines - Physiology and molecular biology - Part I	963	Sprott	Search for the Perfect Synthetic Isoprenoid Glycolipid Vaccine Adjuvant
			1112	Cassone	Cross-kingdom vaccines : dogma and heresy
			969	Smith	Resolution of cancer and infection induced wounding is an essential factor in immune enhancement. The answers to why and how revealed.
Fr	13:15	Antineoplastic agents - New promising mechanisms - Part I	1014	Madhavi	Vaccines: The Magic wand of Indian Public Health?"
			27	Soory	Oxidative stress in periodontal diseases and associated neoplasias: a role for antioxidants?
			1053	Jansen	Clusters of Free Radicals from Dihydroartemisinin Cure Several Parasitic and Viral Diseases. They Attack Cancers by Activating a Series of Apoptotic Pathways and by Causing Strong Angiogenesis Inhibition.
			1086	Scheel-Toellner	Depending on PKC-theta expression, the novel PKC activator PEP005 can either increase or decrease apoptosis of hemopoetic cells.
			715	Wasylyk	Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules
1226	Leamon	Folate Targeted Chemotherapy			
1225	Vlahov	Design and Synthesis of Folate Targeted Chemotherapeutics			

Day	Time	Session	No.	Name	FINAL TITLE
Fr	13:15	Pharmaceutics - Nanoparticles and their latest developments - Part I	260	Mohammadi-Samani	Magnetic nanoparticles for controlled delivery of methotrexate
			421	Sarmiento	Chitosan-stealth polymeric nanoparticles for mucosal insulin delivery
			1236	Lacko	Biocompatible nanoparticles, carriers of the magic bullet.
			1778	Hild	G-Protein Coupled Receptors – New Portals for Nanoparticles in Cellular Drug Targeting?
Fr	13:15	Which role does PK/PD play in drug development?	10000	Derendorf	Streamlining drug development using modeling and simulation
			10000	Schütz	Bioequivalence - Still an Applied Science or already a Cookbook?
			10000	Mouksassi	Modeling and Simulation for Optimal Drug Development in Pediatric Populations
			1638	Kirkpatrick	Titel to be announced
Fr	13:15	Biotechnology of drug delivery	1096	Kohler	Enhanced Potency of Antibodies using biologically active Peptides
			405	Lee	Systematic Discovery of Novel Multi-Target Therapeutics: Finding the New Magic Bullets
			178	Misevic	Selective stimulation of human NK cells proliferation by novel compounds: possible therapeutic use for treating cancer and viral/retroviral infections
			148	Knox	Discovery of dual targeting ligands
			3	Uludag	Designing Bone-Seeking Proteins
			26	Weissig	Intracellular and organelle-specific drug delivery: The new frontier for Magic Bullets

Day	Time	Session	No.	Name	FINAL TITLE
Fr	15:30	Agents / diseases affecting the immune system - Part I	1007	Rahamimoff	The Immunosuppressive Drugs- Cyclosporin A, FK506 and Rapamycin Modulate the Functional Expression of the Na ⁺ -Ca ²⁺ Exchangers in an Isoform Specific Manner
			1411	Saldanha Kubrusly	Polyclonal Rabbit Antiserum Against Porcine-SP-A Able to Detect Human SP-A Using Immunochemical Methods
			719	Korenbaum	Electronic homeopathic preparations as potential Magic Bullet: Pilot study on biologic model
			1119	Song	Alpha 1 Antitrypsin (AAT) for the Treatment of Autoimmune Diseases
			1359	Vannucci	New perspectives in the treatment of melanoma by a glycobiological approach: results in mouse experimental model.
			473	Mittl	Helicobacter cysteine-rich proteins A and -C, two novel signaling molecules form the family of Sel1-like repeat proteins involved in the modulation of pathogen/host interactions.
Fr	15:30	Anti-infectives - Approaches to combat resistance	532	Mlynarczyk	Staphylococci - from full susceptibility to almost full resistance
			1376	Tomblin	Developing a magic bullet against P-glycoprotein-mediated drug resistance by exploiting mechanism
Fr	15:30	Antifungals - Pharmacokinetics and formulation issues	213	Bellmann	Pharmacokinetics and Pharmacodynamics of Amphotericin B and its Lipid Formulations
			797	Biner Orhaner	The pharmacokinetics of voriconazole in children
			219	Egito	MICROEMULSIONS OF AMPHOTERICIN B: A WAY TO CHANGE ITS PROFILE OF ACTIVITY AND TOXICITY.
Fr	15:30	Professional perspectives for health professionals	1812	Fritz	Professional perspectives for health professionals: meeting a pharmaceutical company's top manager
			797	Biner Orhaner	The pharmacokinetics of voriconazole in children
Fr	15:30	Cardiovascular - Drugs acting on the cardiovascular system - Part I	909	Grunnet	Increased repolarization reserve as a new anti-arrhythmic principle
			247	Todorovic	The Acute Effects of Statins in an Experimental Model of Renal Ischemia-Reperfusion Injury
			1380	Pittala	In search of the magic bullets: discovery of RN5 and its structural modifications for targeting selectively alfa1 adrenoceptors
			300	Nishio	Effect of Insulin Resistance on In-Stent Restenosis after Coronary Stenting in Type 2 Diabetic Patients
			1752	Kreimeier	Effects of Small-volume Resuscitation Using Hyperosmolar Saline Colloid Solution on Regional Blood Flow and Ischemic Tissue Injury
			1773	Kubitz	Levosimendan – More than an Inotropic Agent ?

Day	Time	Session	No.	Name	FINAL TITLE
Fr	15:30	CNS - Pharmacological options in disease of the central nervous system - Part II	1342	Del Valle Mojica	Effect of Valeriana officinalis extracts in [3H] Glutamate Binding
			1346	Ortiz	Interactions between cocaine, EAAT and NO
Fr	15:30	Clinical studies with agents of different pharmacological activity - Part I	1388	He	Increase of fibrin network porosity and the consequent fibrinolysis as an anticoagulant effect of acetylsalicylic acid
			1315	Dougherty	L-tryptophan as a Research Compound and Therapeutic Agent
			1167	Usha	Clinical Efficacy and Safety Evaluation of Roxithromycin in Rheumatoid Arthritis – An Open Label Study.
			217 253	Jansen Restivo Pantalone	Sulfasalazine Revisited: A Multi-Targeted Magic Bullet LONG-TERM SEQUENTIAL DEFERIPRONE-DEFEROXAMINE VERSUS DEFERIPRONE MULTICENTER RANDOMISED CLINICAL TRIAL FOR THALASSEMIA MAJOR PATIENTS: DECREASE IN MORTALITY.
Fr	15:30	Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part II	68	Plotkin	Silencing Cell-Cell Communication: The New Bullets in Anti-Infectives
Fr	15:30	Nerve diseases, mechanisms, and pathophysiology - Part I	1181	Alessenko	PROTECTIVE EFFECT OF DIMEBON ON THE TNF-a –INDUCED LIPID DISORDERS IN MICE BRAIN
			714	Petry	MRI monitoring of blood brain barrier alterations in inflammatory lesions of Multiple Sclerosis: Tools to evaluate disease activity, efficacy of treatments and to develop new therapeutic strategies
Fr	15:30	Pharmaceutics - Discovery of drugs and mechanisms - Part I	30	Broglia	The design of drugs which do not create resistance: folding inhibitors
			131	Ema	Process Research on a Key Synthetic Intermediate of Clopidogrel
			20	Jacoby	Key Aspects for the Compilation and Enhancement of a Comprehensive Chemogenomics and Drug Discovery Compound Screening Collection

Day	Time	Session	No.	Name	FINAL TITLE
Fr	15:30	Cytochrome P450 - in vitro studies - Part I	1341	Jachymova	Using Chimeras with C-Terminal Tails NOSs for Probing of the Electron Traffic in CYPOR
			892	Spasojevic	Anti- and pro-oxidant actions of metalloporphyrins in mimicking SOD, peroxyredoxin, and cyt P450
			451	Veeger	Physico-Chemical Insights in Biological Conversions; the Role of H2O as driving Force in Cytochrome P450 catalysis
Fr	15:30	Antibacterials - Discovery - Peptide antibiotics - Part I	621	Sahal	Designing Peptidic Magic Bullets Against Bacteria
			1310	Sari	Production of cystine rich peptides and protein in E. coli: hepcidin, the iron-regulating hormone.
			843	Sonomoto	Lantibiotics: insight and foresight for new antimicrobials; Structure-function relationships, mode of action, molecular mechanisms of immunity (resistance), lantibiotic engineering
Fr	15:30	Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part I	54	Abo-EL-Sooud	EFFECT OF FLUNIXIN ON ENROFLOXACIN CLEARANCE AND STEADY-STATE SERUM CONCENTRATIONS IN CALVES
			1015	Wetzstein	Magic Bullets: Once Fired – How are They Recaptured? On the Metabolic Transformation and Environmental Fate of the Veterinary Fluoroquinolone Enrofloxacin
			242	Alkadi	Effect of gentamicin on serum digoxin level in patients with congestive heart failure
			1249	Lavy	Controlled Release Amoxicillin Therapy in Veterinary Medicine
Fr	15:30	Atherosclerosis, stroke & aging - mechanisms and treatment - Part I	550	Birnbaum	Modification of the Infarct Size Limiting Effects of Statins by Antiplatelet Drugs
			1195	Sharma	Intragraft Administration Of Abciximab And Verapamil Combined With Direct Stenting Prevents Slow-Flow And No-Reflow Phenomenon In Saphenous Vein Graft Percutaneous Coronary Intervention

Day	Time	Session	No.	Name	FINAL TITLE
Fr	15:30	Antidepressant drugs and their mechanism of action Part I	55	Irman-Florjanc	New Features of Antidepressant Drugs - Modification of Histamine Kinetics
			602	Bogeso	Escitalopram-the first ASRI. A Magic Bullet in the treatment of depression and anxiety
			799	Garcia	Photophysics, Photochemistry and induced-Photoallergy of Tricyclic Antidepressants
Fr	15:30	Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part I	197	Vitek	Anticancer effects of statins
			630	Uemura	Antitumor potency of angiotensin II receptor blocker for prostate cancer
			482	Lothstein	Cardioprotective Anthracycline PKC Activators for The Treatment of Drug-Resistant Tumors
Fr	17:30	Cardiovascular - Drugs acting on the cardiovascular system - Part II	125	Rodriguez	Systemic Immunosuppressive Therapy with Oral Sirolimus After Bare Metal Stent Implantation: The Missing Alternative in the Prevention of Coronary Restenosis After Percutaneous Coronary Interventions.
			239	Arsenal	CARDIAC TAMPONADE SECONDARY TO SLINGSHOT METAL DART : A RETROSPECTIVE REVIEW OF CASES
			321	Palmer	Structure Based Design of Second Generation PDE5 Inhibitors
			304	Höcht	Pharmacokinetic-Pharmacodynamic modeling of calcium channel blockers in animal models of hypertension.
Fr	17:30	Antineoplastic agents - Effectiveness and resistance in patients - Part II	1066	Ardies	Using Exercise as a Modality to Identify Therapeutic Molecules for Treatment & Prevention of Cancer-Associated Cachexia
			893	Liebes	Para-aminobenzoic acid and a novel analog enhances the antitumor activity of ionizing radiation and chemotherapy drugs. Results from preclinical studies and a phase I study with stage IV melanoma patients.
			1033	Sevilla	Spectroscopic study on the interaction of the antitumoral drug emodin with bovine serum albumin: fluorescence, circular dichroism, SERS, SEF and stopped-flow techniques

Day	Time	Session	No.	Name	FINAL TITLE
Fr	17:30	Mechanisms of inflammation and anti-inflammatory agents - Part I	23	Ruysschaert	Cationic liposomes:how a magic bullet turns into an anti-inflammatory agent.
			1212	Noda	Brain• fs immune cells and anti-inflammatory effects of neuropeptides
			308	Haerdi-Landerer	Magic Bullets for Joint Treatment. Why Doxycycline?
			406	Zachariae	Methotrexate in Dermatology through 50 Years
Fr	17:30	Physiology & Magic Bullets - Part I	1030	Romani	Isoproterenol and Insulin: the Ying-Yang of regulation of Mg ²⁺ homeostasis in mammalian cells
			696	Assounga	Transcription of Major Histocompatibility Complex Class I (Kb) and Transporter Associated with Antigen Processing 1 and 2 genes is up-regulated with age
Fr	17:30	Analgesia & analgetic drugs - Part I	1028	Heavner	Cardiotoxicity Plagues Bupivacaine
			413	Ayar	Levetiracetam in the treatment of neuropathic pain: evidence from cellular and behavioral pain models
			593	Saeidian	Under-treated painful condition may lead patients to opioid abuse
Fr	17:30	Drug transporters and delivery - Part I	1217	Oosterhuis	Transporter Mediated Drug-Drug Interactions: Modulation of Drug Absorption by Environmental Toxicants
			684	Paine	Predicting the Impact of Hepatic Transporters on the Pharmacokinetics of Statins in the Liver
Fr	17:30	Transporters of physiological compounds and drugs - Part I	67	Chen	Na-Coupled Bicarbonate Transporters: Expression, Structure and Function
			232	Tor	Aminoglycoside Derivatives as Drug Transporters: Delivery Magic Bullets?
			586	Katsuragi	Ca ²⁺ -signal transducing system from the endoplasmic reticulum to mitochondria involved in the caffeine-inducible ATP transport
Fr	17:30	Antibacterials - New mechanisms and delivery strategies - Part I	279	de Carvalho	Effect of antineoplastic agents on the surface properties of bacterial cells.
			781	Iwabuchi	The role of lipid rafts in host-pathogen interactions: Involvement of lactosylceramide-enriched lipid rafts in innate immunity and mycobacterial infection
			862	Gaspar	Liposomal Rifabutin: an efficient drug delivery system for the treatment of mycobacterial infections

Day	Time	Session	No.	Name	FINAL TITLE
Fr	17:30	Clinical studies with agents of different pharmacological activity - Part II	358	Ophir	25-Years of Sight Saving by Preventing Postoperative Scarring with Local Use of Antimetabolites.
			930	Varkonyi	Preliminary results of the Semmelweis Budapest Mastocytosis Center
			1074	Lavoie	Vitamin C in intravenous nutritive solution: double-edge effect for premature newborn infants
Fr	17:30	Antineoplastic agents - Delivering a Magic Bullet to its target(s) - Part I	1317	Wang	New multifunctional pharmacophores and biocompatible nanocomposites for targeting drug delivery and cancer diagnosis
			871	Oku	Efficient cancer therapy by use of neovascular-targeted liposomes.
			528	Lewis	Chemoembolisation Using Drug Eluting Beads: Magic Bullets Targeted by Arterial Guidance.
Fr	17:30	Antineoplastic agents - Personalized therapy - Part I	10001	Fuhr	Application of pharmacokinetics of individualize antineoplastic therapy
			980	Dai	Personalized Prevention of Colorectal Neoplasia: High Magnesium and Low Calcium among People with a Functional Polymorphism in the Magnesium Transporter
			555	Waters	When More is Not Necessarily Better: Interdisciplinary Inquiry into the Implications of U-shaped Dose Responses for Personalizing Anticancer Interventions
			691	Grim	PK/PD of low dose methorexate
			251	Huck	Characterised Nanomaterials for Biomarker Profiling Based Cancer Detection
Fr	17:30	Antiparasitic compounds - Magic Bullets against various parasites	192	Müller	Diagnosis and Innovative Therapy of Human specific Enterocytozoon bienewisi Genotype D Strain in Falcons (Falconiformes)
			1045	Yu	The fecundity of Schistosoma japonicum was impaired by administration of low dose cyclophosphamide
			516	Makunde	A Randomized Double Blind Two Arms Community Trial to Assess Activity of Doxycycline on Bancroftian Filariasis Worm Nests, Orchitis, Hydrocoele and Sub-clinical hydrocoele
			1464	Dika	Percutaneous absorption of crotamiton in man following single and multiple dosing.

Day	Time	Session	No.	Name	FINAL TITLE
Fr	17:30	Antivirals - Clinical effectiveness	510	Gigi	Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects
			669	Kotwal	Enveloped virus neutralizing antiviral compounds, the magic bullets against a broad spectrum of deadly viral diseases.causing a billion infections annually around the globe
			181	Gunawardena	Re-infection with Varicella Zoster in older people
			828	Serin	Detection Of Lamivudine And Adefovir Resistant Hepatitis B Virus Polymerase Gene Variants During Two Years Antiviral Therapy Of Chronic Hepatitis B Patients In The South Of Turkey
			282	Dunin-Wasowicz	Ganciclovir treatment of infants with cytomegalovirus infection and central nervous system involvement
			564	Malhotra	Spectrum and risk for HIV-1 associated mutations and the efficacy of antiretroviral therapy among infected pediatric patients
			536	Welsch	Residue Networks and Drug Resistance in Hepatitis C Virus Antiviral Therapy
Fr	17:30	Biosimilars / Follow-on Proteins and their challenges to manufacturers and regulatory bodies - Part I	1803	Schneider	Biosimilars - EMEA's point of view
			10000	Sörgel	Phase I - study of an erythropoietin biosimilar
			10010	Jusko	Bioequivalence of biosimilars - is pharmacodynamic equivalence sufficient?
			10000	Brockmeyer	Developing a biosimilar
Fr	17:30	Cardiovascular - Pharmacological action in the cardiovascular system from small molecules to peptides and vaccines - Part I	1180	Waldmeier	Absorption and Disposition of the Renin Inhibitor Drug Aliskiren
			706	Razavim	The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients with Coronary Artery Diseases (IVCAD)
			1751	Frieß	Formulation Challenges in Biologics

Day	Time	Session	No.	Name	FINAL TITLE
Fr	17:30	Treatment of asthma, COPD, and other lung diseases - Part I	299	Volovitz	Budesonide - Breath-giving innovation for asthma patients
			834	Martinez-Giron	NEW HORIZONS IN RESPIRATORY ALLERGY THERAPY AND "MAGIC BULLETS": COULD IT BE POSSIBLE TO INCLUDE ANTIPROTOZOAL DRUGS?
			431	Bansal	Synthesis of a Series of 8-(Substituted-Phenyl)xanthines and a Study on the Effects of Substitution Pattern of Phenyl Substituents on Affinity for Adenosine A1 and A2A Receptors- The Magic of Theophylline
Fr	17:30	Immunosuppressants - Part I	885	Mourad	Pharmacogenetic and pharmacokinetic approaches in renal and hepatic transplantation
			1208	Wagner	NVP-AEB071: Oral and Specific Inhibitor of T cell Activation for the Prevention of Graft Rejection and the Treatment of Autoimmune Diseases
			248	Chen	Blocking Effect of an Immuno-Suppressive Agent, Cynarin, on CD28 of T-Cell Receptor Found by a Novel Pharmaceutical Method
Fr	20:00	New drug concepts	921	Degtyarenko	Open chemical databases and ontologies in the genomic age
			1016	Koppenol	Energetics of Cytochrome P450 Hydroxylations: Making Sense of In Silico
			959	Honkanen	Inhibitors of Serine/Threonine Protein Phosphatases at the Dawn of a Clinical Era.
			1197	Petrenko	COMBINATORIAL NANOBIO TECHNOLOGY - A PARADIGM SHIFT IN CHEMISTRY AND MATERIAL SCIENCE
			638	Janciauskiene	Alpha1-antitrypsin augmentation therapy: new insights into the molecular basis of efficacy
			261	Horak	What Sort of Light Is At the End Of the Tunnel In Anti-Allergic Drugs?
Fr	20:00	Pharmaceutics - Drug delivery through the skin - Part I	150	Squier	Penetration of Bioactive Proteins and Peptides across Stratified Mucosae in a Porcine Ex-Vivo Model
			113	Stinchcomb	Transdermal Delivery of Naltrexone, In Vitro Testing to Human Volunteers
			631	Lecybyl	Fentanyl: How delivery system can modify clinical properties of molecule
			1177	Alvarez-Lorenzo	Hydrogels for sustained and selective release of diclofenac
Fr	20:00	Vaccines - Antiinfectives - Bacteria and parasites - Part I	1170	Sauerwein	Malaria vaccines for the better
			955	Baker	Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of age

Day	Time	Session	No.	Name	FINAL TITLE
Fr	20:00	Pharmaceutics - Reviews and general aspects	913	Kondaj	Pharmaceutical Policy in Context of Health care System in Albania
			616	Gonzales	Medicinal effects of maca: Experimental data on reproduction, memory and learning
			897	Pezehk	A Cost -Benefit Approach to Sample Size Determination for Clinical Trials with Binary Responses
			722	Kingsford-Adaboh	Exploiting Plant Sources for Potential Drugs. Alpinumisoflavones in Perspective
			1511	Patel	Biopharmaceutical and Pharmacokinetic Searches of Drugs in Perinatology (1968-2008)
			1345	Al Mosawi	The role of ancient Iraqi People (Sumerian, Assyrian, Babylonian and Arabian) in the development of medicine as viewed by western writers
Fr	20:00	Pharmacokinetic studies and drug metabolism	540	Amini	Pharmacokinetic study of rivastigmine in Iranian healthy subjects following 3 and 4.5 mg dosing using a simple and sensitive HPLC-UV method
			1031	Cook	Role of drug metabolism in the development of Eplerenone: A lesson learned from Spironolactone
			1302	Akiyama	Pharmacokinetic Study of Saltz Regimen for Advanced Colorectal Carcinoma under Hemodialysis
			558	Reyes	BIOEQUIVALENCE AND PHARMACOKINETIC STUDIES OF FIVE ANTIRETROVIRAL GENERIC DRUGS IN HIV/aids CUBAN PATIENTS
			184	Odeku	Generics versus originator drugs: Analysis of paracetamol and Ibuprofen tablets in the Nigerian Market
			679	Mukherjee	Indocyanine green-revisiting an old friend.

Day	Time	Session	No.	Name	FINAL TITLE
Fr	20:00	Therapeutic Proteins - clinical studies - Part I	452	Idro	Can Erythropoietin be used to prevent brain injury in children with cerebral malaria?
			103	Wong	Applications of recombinant human epidermal growth factor in the treatment of hard-to-heal wounds
			1311	Shimura	A Bevacizumab, An Anti-VEGF Antibody, As A MAGIC BULLET for Retinal Disease?
			1231	Murasugi	Optimized Productions of Recombinant Human Proteins, an Enzyme and Two Cytokines, in Fermentor Cultures of the Yeast, <i>Pichia pastoris</i>
			786	Vadrevu	Commercialization of Recombinant Human Epidermal Growth Factor – A Nobel Prize Winning Molecule with Diverse Therapeutic Applications
			1263	Kelly	Designing Novel Drugs for Neurological Disorders: The Development of TRH-based Neurotherapeutics
Fr	20:00	Biosimilars / Follow-on Proteins and their challenges to manufacturers and regulatory bodies - Part II	821	Bendtzen	Immunogenicity of biopharmaceuticals - An inconvenient truth
Fr	20:00	Vaccines - Targeting non-infectious diseases - Part I	1256	Katoh	EMY162 Protein as a Vaccine Candidate to Reduce Level of Alveolar Hydatid Disease
			816	Cirla	TREATMENT AND RELOCATION OF WHEAT FLOUR SENSITIZED WORKERS BY AN ALLERGENIC VACCINE
			903	Fry	Psoriasis [Ps]: A Possible Candidate for Vaccination
			956	Barabas	The Modified Vaccination Technique developed by Barabas provides the “magic bullet” for the prevention and cure of chronic ailments such as autoimmune disorders and cancer specifically, without side effects

Day	Time	Session	No.	Name	FINAL TITLE
Fr	20:00	Anti-infectives - Mechanisms of bacterial resistance - Part I	162	Kumarasinghe	Resistance, Including Carbapenem Resistance, Among Enterobacteriaceae In a University Hospital In Singapore
			1294	Peng	Functional characterization of outer membrane proteome in response to antibiotic resistance
			1047	Ozgunus	A Molecular Perspective on Integron-Associated and Transferable Antibiotic Resistance in Clinical and Aquatic Isolates of Gram-Negative Bacteria in Northern Region of Turkey
			140	Shafer	Bacterial drug efflux pumps: significance for antibiotic resistance and pathogenicity.
			1313	Talukder	Mechanism of Fluoroquinolone resistance in Shigella and Salmonella species
Fr	20:00	Antineoplastic agents - Clinical trials and approaches- Part I	1518	Nishida	Cryoimmunology induced after reimplantation of malignant bone tumor treated with liquid nitrogen
			92	da Fonseca	Ras as a target for exploratory study of monoterpene perillyl alcohol intranasal administration in patients with recurrent gliomas
			328	Wiela	Methotrexate – the past and the present
			591	Wang	Magic bullet and magic shield: a new strategy to target Survivin in human cancers
			1314	Maran	Estrogen Metabolites in the Control of Osteosarcoma
			466	Adhvaryu	Prevention of Mucositis and Improvement in Compliance of Head & Neck Cancer Patients undergoing Radio-Chemotherapy by Curcumin
Fr	20:00	Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part I	615	Stasko	Heparin as an antineoplastic agent?
			182	Gourdeau	TLN-4601, a novel anticancer agent inhibits Ras signaling through Raf-1 degradation
			13	Suzuki	L-type-like calcium channels in non-excitabile cells: critical roles in cell survival
			769	Munaron	Calcium signaling and angiogenesis
Fr	20:00	Antiparasitic compounds - Malaria Therapy and approaches	1080	Bag	Antibacterial, Antisecretory and Antihemorrhagic Activity of Azadirachta indica Used to Treat Cholera and Diarrhea in India
			96	Biswas	Epidemiology of Malaria in India and Intervention Measures
			993	Kongpatanakul	Comparative Study of Dihydroartemisinin and Artesunate Safety in Healthy Thai Volunteers
			1125	Syafruddin	Antimalarial drug resistance in Indonesia: A molecular analysis

Day	Time	Session	No.	Name	FINAL TITLE
Fr	20:00	Blood-brain barrier - History and most recent finding - Part II	269	Begley	Paul Erlich: The blood-brain Barrier and the search for the magic bullet.
			343	Björkhem	Brain cholesterol ? Long secret life behind a barrier
			19	Braissant	Poor permeability of blood brain barrier for creatine: Autonomous brain synthesis of creatine, and consequences for creatine deficiency syndromes
			1001	Kalasz	Peculiarities of Blood-Brain-Barrier Penetration of Pralidoxime
Fr	20:00	Treatment of diseases with involvement of the immune system - Part II	1141	Avunduk	The Effect of Melatonin and Zinc on the Immune Response in Experimental Toxoplasma Retinochoroiditis
			293	Joseph	Short-term, low dose methotrexate: a regimen for immune tolerance induction
			1130	Malemud	Potential of JAK/STAT inhibitors for treating RA
			39	Kwiatkowska-Patzer	Oral tolerance as a method of suppression of immunological response in experimental autoimmune encephalomyelitis
			718	Bertok	RADIODETOXIFIED ENDOTOXIN AS IMMUNOMODULATOR (A new "MAGIC BULLET")
			1032	Cragg	Mechanisms of anti-CD20 immunotherapy: Why Type II mAb are better
Fr	20:00	Pharmaceutics - Pharmacokinetics and drug formulations - Part I	938	Hermann	Which gliclazide (GLC) formulation tablets, immediate (IR) or modified release (MR), are better therapeutic choice?
			52	Otagiri	Reduction of Flubiprofen-Induced Gastric Toxicity by Prodrug Formation and Enhancement of Oral Bioavailability of Flubiprofen by Chitosan Complexation
			907	Kennedy	DRUG ABSORPTION FROM THE SMALL INTESTINE IN IMMEDIATE POSTOPERATIVE PATIENTS
			1372	Al-Kassas	controlling of systemic absorption of gliclazide through incorporation into alginate beads
			118	Fagerholm	The use of permeability and reference compound data for predictions and understanding of human pharmacokinetics

Day	Time	Session	No.	Name	FINAL TITLE
Fr	20:00	Vaccines - Antiinfectives - Malaria & Tuberculosis	1182	Haile	Studies on New Tuberculosis Vaccine Candidates in Animal models
			1303	Andrade Santana	CONSTRUCTION -DEPENDENT DNA LIPOSOME EFECTIVENESS ON TUBERCULOSIS VACCINATION
			1011	Cardona	The dynamic hypothesis of latent tuberculosis infection offers a new rational to develop future therapeutic strategies.
			982	Porter-Kelley	Cultured Plasmodium Sporozoites as a Potential Malaria Vaccine
			329	Pesut	Status of BCG vaccine at the beginning of the 21st century
			761	Tsuji	Title: Severing the Gordian Knot: Are Glycolipids the solution for Effective Vaccines against Malaria and HIV?
Sa	07:15	Agents / diseases affecting the immune system - Part II	1129	Paczesny	A biomarker panel for acute graft versus host disease
			25	Adams	Magic bullets against the autoimmune diseases
			728	Stenberg	The Pathogenesis of Autoimmune Diseases: New Possibilities for Drug Development
			1035	Arkipova	Differently Directed Changes in Interferon- γ Production Depending on Radioadaptive Response.
			147	Schoonen	High Throughput Screening for In Vitro Toxicity Screening: A Gradual Acceptance of New Test Methods
			427	Mitchell	Toll-Like Receptor (TLR) Agonists and the Induction of the Innate Immune Response
			1211	van Rossum	Pharmacodynamic monitoring of calcineurin inhibition therapy
Sa	07:15	Analgesia & analgetic drugs II	801	Prandota	Valproic Acid (VA) May Be Effective in the Treatment of Headaches Associated with Reactivation of Cerebral Toxoplasmosis (CT)
			204	Simonin	Neuropeptide FF receptors: a novel target for pain treatment
			717	Slanar	Genetic aspects of tramadol PK and PD
			1305	Leppert	Quality of life in patients with cancer pain treated by controlled release tramadol and dihydrocodeine
			1255	Boules	Neurotensin Agonists: Novel Analgesics with Synergy to Morphine

Day	Time	Session	No.	Name	FINAL TITLE
Sa	07:15	Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part III	1609	Holzgrabe	The piggy back approach or how to find new lead structures for antiinfective or antiviral drugs
			1159	Severa	The new biocidal agents with the high sporicidal efficiency
			179	Biava	New derivatives of BM 212 with improved antimycobacterial activity.
			686	Boukraa	Rediscovering antibiotics of alternative medicine: case of apitherapy
			673	Lagaron	Desining Novel Antimicrobial Concepsts Combining Nanotechnology, Bioplastics and Natural Products
Sa	07:15	Anticoagulation and heparin-based drugs	345	Liu	An enzymatic approach for developing heparan sulfate-based drugs
			462	Laux	Innovation in Anticoagulation: The Discovery and Development of Novel Small Molecule Coagulation Inhibitors as New Treatment Option for Thromboembolic Diseases
			772	Liu	Trans-lymphatic Chemotherapy
			1374	Brophy	A Therapeutic Conundrum: Low molecular weight heparins in patients with kidney dysfunction.
			106	Deckmyn	Antithrombotics that do not induce bleeding: the "holy grail" found by interfering with von Willebrand factor
Sa	07:15	Antifungals - Optimizing treatment in normal and special populations	1088	Dhar	Antifungal therapy in cardiothoracic transplant recipients in a new prescribing era
			1297	Rhomberg	Vindesine and Razoxane, an Effective Drug Combination for Soft Tissue Sarcomas
			1143	Thongprasom	Antifungals in the treatment of candidiasis eruption during treatment oral autoimmune diseases
			841	Veroux	Newer antifungal drugs in kidney transplant recipients
			641	Podobnik	Treating fungal infections with CYP53A15 inhibitor

Day	Time	Session	No.	Name	FINAL TITLE
Sa	07:15	Antineoplastic agents - in vitro and in vivo	935	Schepkin	Sodium and Diffusion MRI as Biomarkers of Initial Tumor Response to Therapy in Rodents
			59	Chou	The Therapeutic "Cure" of Xenograft Tumors by the Third Generation Epothilone: Iso-oxazole-Fludelone
			725	Gil-Ad	Evidence for anti cancer activity for the anti depressant sertraline, in vitro and in vivo effect in nude mice xenografted with HT29 cells.
			751	Filippich	The pharmacokinetics, pharmacodynamics and clinical trials of platinum analogs in birds
			1292	Rephaeli	Prodrugs of histone deacetylase inhibitors in combination with doxorubicin impart improved anticancer activity and reduced toxicity by differentially affecting tumor versus normal tissue
Sa	07:15	Antineoplastic agents - New mechanisms & compounds - Part II	1110	Momparler	Epigenetic Therapy using 5-Aza-2'-deoxycytine: A Magic Bullet Against Cancer
			132	Moll	Cell cycle kinases as molecular targets in anticancer therapy
			117	Injac	»Carbon bullet«: Fullerenol C60(OH)24 as organo-protector against doxorubicin-induced toxicity
			1334	Wondrak	'Targeting the Redox Achilles Heel of Cancer Using NQO1-Activated Phenothiazinium Redox Cyclers'.
			138	Kusuzaki	Acridine orange found in Ehrlich's era could become a "Magic Bullet" against cancer under photon energy
Sa	07:15	Bioanalytics - The cutting edge of LC-MS/MS - Part I	16	Zhao	The combined use of HPLC, Gel-LC-MS/MS and microarray in monitoring product quality and safety for gene therapy
			63	Bischoff	LC-MS for label-free biomarker discovery
			619	Oiestad	Drug Screening of Preserved Oral Fluid by Liquid Chromatography-Tandem Mass Spectrometry
			339	Trontelj	Liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its two glucuronide metabolites in human plasma and serum

Day	Time	Session	No.	Name	FINAL TITLE
Sa	07:15	Clinical studies with agents of different pharmacological activity - Part III	44	Cerwenka	Treatment of hepatic abscess: Magic bullets and beyond
			1284	Shrivastava	Prospective Magic Bullet Cobalt: Its Effect, Mode of Action and Utility for Hypoxic Study
			521	Brunner	Magic bullets for the treatment of inflammatory bowel disease - yet to come?
			315	Rozman	Genetic polymorphisms of cytochromes P450 influence the Leflunomide treatment and toxicity in rheumatoid arthritis patients
			368	Choudhry	Deferoxamine and Defersirox as magic bullets against iron overload
Sa	07:15	CNS - Pharmacological options in disease of the central nervous system - Part III	1401	Decimo	Neuronal trafficking of proteins involved in synaptic plasticity: a GFP-based approach
			1394	Köves	Secretin and Autism
			62	Kaur	Melatonin-a possible magic bullet in reducing hypoxic brain injury
			1040	Atlas	MAGIC BULLETS FOR THE TREATMENT OF OXIDATIVE STRESS-INDUCED NEURODEGENERATIVE DISORDERS
			267	Berkels	Lacosamide is a Novel Antinociceptive and Antiepileptic Drug with a Dual Mode of Action
			798	Isokawa	Caffeine sets the brain's excitability by priming the activation of the endogenous cannabinoid system
			1309	Yasuo	Atorvastatin protects spinal motor neurons from glutamate mediated neurotoxicity
Sa	07:15	Doping and performance enhancement drugs	270	Holt	Growth Hormone: how to catch the magic bullet of the modern athlete
			583	Petroczi	Magic bullet or magic diet: The need for further understanding in sport performance enhancements
			595	Vitali Serdoz	ILLICIT DRUGS AND CARDIAC ARRHYTHMIAS IN ATHLETES
			991	Tsuchida	Myostatin Inhibiting Peptide Works as a Magic Bullet to Increase Skeletal Muscle Mass and to Ameliorate Muscle Pathology in Muscular Diseases by Transgenic Expression

Day	Time	Session	No.	Name	FINAL TITLE
Sa	07:15	Pharmaceutics - Discovery of drugs and mechanisms - Part II	789	Bogdanova	Purposeful Drug-Excipients Physico-Chemical Interactions – What does that mean for Optimization of Drug Delivery and Safety?
			327	Walles	Bioartificial Human Tissues as Model Systems for Pharmaceutical Target Screening and Drug Development
			1150	Díaz Perales	CROSS-REACTIVITY AND IDENTIFICATION OF T AND B EPITOPES IN PLANT FOOD ALLERGENS: PEACH PRU P 3 AS A MODEL
			139	Ohlson	Transient Drugs as Magic Bullets: A New Approach to Drug Discovery
			154	Nikolelis	Modulation of the structure of a lipid membrane for selective interactions with a drug
Sa	07:15	Physiology & Magic Bullets - Part II	809	Belyaeva	Mitochondrial Respiratory Chain (MRC) and Mitochondrial Permeability Transition (MPT) Effectors against Heavy Metal-induced Cytotoxicity: State-of-the-art and Perspective
			977	Fukuda	Chelating Agents for Treatment of Uranium-induced Toxicity in Radiation Emergency Medicine
			804	Sherlina	Activation of LINE DNA in realization of adaptive response
			808	Strunecka	Fluoride and Aluminum Interactions: AIFx as the MAGIC BULLETS Producing Aberration of G Proteins
			151	Abe	A role for lysosomal phospholipase A2 in cationic amphiphilic drug-induced phospholipidosis. (Oral form)
			1087	Tsetlin	Snake and snail neurotoxins – magic tools for targeting different subtypes of nicotinic acetylcholine receptors
Sa	07:15	Recombinant Proteins - a new class of Magic Bullets- Part II	642	Oestergaard	Kinetic Properties of Recombinant Factor VIIa (rFVIIa) and the Complexity Relating these to Treatment Response
			371	Smajilagic	PHARMACOKINETICS AND BIOLOGICAL EFFECTS OF THE RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-7 IN VIVO
			662	Tini	Dissecting the DNA Base Excision Repair Pathway: Implications for Cancer Therapy
			984	Kuwata	Dynamics Based Design of Anti-Prion Compounds Uncovered the Hot Spots for Prion's Pathogenic Conversion Reaction
			905	Pedersen	Metallic gold reduce TNF? expression, oxidative DNA damage and pro-apoptotic signals in brain injured mice.
			807	Kanduc	Epitopic Peptides with Low-Similarity to the Host Proteome. Towards the Magic Bullets

Day	Time	Session	No.	Name	FINAL TITLE
Sa	07:15	Biomarkers - The thorny way to personalized medicine	610	Fierz	It's not only genes - The many dimensions of personalized medicine
			831	During	CURRENT KNOWLEDGE ON TRANSPORTERS OF VITAMIN A AND ITS PRECURSORS
			1402	Guvakova	Transient Activation of the Small GTPase Rap1 is Functionally Required for the Regulation of Breast Cancer Cell Motile Responses to IGF-I
			65	Roukos	Personalized management of breast cancer: Promises and Challenges of Genetic Testing and Genomewide Association Studies
			77	Suzuki	Personalized Medication with Estramustine Phosphate for Advanced Prostate Cancer after Screening of the CYP1A1 gene polymorphisms
			152	Li Wan Po	Pharmacogenomic targetting of Ehrlich's magic bullet
			1265	O'Driscoll	New Biomarkers and Targeted Therapies for Breast Cancer
Sa	07:15	Antineoplastic agents - how to find new Magic Bullets	168	Mezo	Novel Antineoplastic Agent – Peptide Conjugates as Drug Delivery Systems for Targeted Chemotherapy
			1243	Kumagai	Anticancer activities of vitamin D analogs
			1162	Tacke	Titanium-Based Magic Bullets Against Renal-Cell Cancer
			28	Suck	Inhibitory Effects of Demecolcine on NK Cell Functions: Implications for Cancer Therapy
			172	Richards	Asparagine Synthetase Inhibitors with Nanomolar Potency: An Unexplored Approach to Treating Drug-Resistant Leukemia
			88	Williams	INVESTIGATION OF DIBENZYL TRISULPHIDE (DTS) ISOLATED FROM PETIVERIA ALLIACEA AS AN IMMUNOMODULATOR WITH CYTOTOXIC/ANTI-PROLIFERATION ACTIVITY
			Sa	07:15	Clinical situations & therapy and cellular therapeutics
759	Lenkovsky	Metoclopramide Does Not Influence the Incidence of Propofol-Induced Spontaneous Movements			
91	Kummoona	Missile Injuries Of Orofacial Region, Primary and Secondary Management			
1326	Bieberich	The insulin-stem cell connection: what insulin does to stem cells and how we get it from them			
1149	Mobbs	The Psychological Outcome of Male Constitutional Delay Short Stature			
1254	Doronin	Adult stem cells are a source of paracrine factors for tissue regeneration			

Day	Time	Session	No.	Name	FINAL TITLE
Sa	07:15	Endocrinology including diabetes	155	Koga	Targeting Cell Cycle Progression by Troglitazone.
			36	Stefanovic	Dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus
			1205	Kudolo	Towards a Magic Bullet for the Metabolic Syndrome – Use of the Ginkgo Biloba Extract
			1082	Wada	Drug discovery related to vaspin, visceral adipose-tissue derived serine protease inhibitor, a novel adipokine with insulin-sensitizing effects.
			1485	Aycan	Insulin, IGF-1 and Rosiglitazone: How Do They Effect The Glucose Metabolism and Insulin Resistance in Human SH-SY5Y Cells with Alzheimer Key Proteins?
			752	Kador	The Importance of Appropriate Animal Models for Evaluating Agents for Proliferative Retinopathy: Failure of Combretastatin to inhibit Diabetes-Like Proliferative Retinopathy in the Galactose-Fed Dog
Sa	07:15	Illicit drugs & similar agents and addiction	643	Liechti	Ecstasy – The Pharmacology of Happiness
			698	Chiappelli	Cellular Immune Toxicity of Alcohol and Cocaine: Medical Practice Based on the Evidence vs. Evidence-Based Medical Practice
			915	Loland	Identification of the cocaine binding site on the dopamine transporter
			802	Gu	Dopamine transporter as the target and carrier of illicit and therapeutic drugs – PK/PD approaches to develop MAGIC BULLETS for cocaine abuse
			361	Kedia	Political Economy and Societal Consequences of Methamphetamine Epidemic in the United States
			810	Stenbacka	Illicit drug use and injuries

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Target site interactions and spectroscopic / computational approaches	999	Kulikov	New animal models for psychotropic drug-drug interactions
			975	Frelek	Circular dichroism spectroscopy in stereochemical studies of b-lactam antibiotic analogues
			1333	La Hoste	Interactions Between Drug Target Binding Sites and the Remarkable Story of Dopamine D1/D2 Synergism
			847	Dillon	Dissociation of Multi-molecular Drug Complexes and Multi-site Binding to 7-TM Receptors: Protection, Delivery and Enhancement of Adrenergic Activation by Ascorbate
			996	Matsumoto	Consideration of Metachromatic Spectral Changes of Toluidine Blue Staining of DNA Depending on its Helical Structure
			1115	Gresh	Molecular modelling of inhibitor-kinase interactions. 'Icy', highly polarized water molecules can tip the relative energy balances of competing inhibitors
Sa	09:30	Pharmaceutics - Experimental and computational approaches - Part II	970	Popelier	Modern quantum chemical descriptors for QSAR/QSPR
Sa	09:30	Antibacterials - Clinical Aspects - Part II	9	Ram	Effectiveness Of Antibiotics In The Management Of Acute Exacerbations Of Chronic Obstructive Pulmonary Disease. Do Antibiotics Improve Patient Outcomes – Evidence To Date
			857	Jashari	Decontamination of Cardiovascular Allografts in European Homograft Bank (EHB). Comparison of different Antibiotic Cocktails in low Concentration low Temperature Conditions
			927	Radhakrishnan	Addition of Local Antiseptic Spray to Antibiotic regime reduces the incidence of stomal infection following Percutaneous Endoscopic Gastrostomy (PEG) – a randomised controlled
			1100	Nelson	Antibiotic treatment of Clostridium difficile - does it work?
			393	Abu-Youssef	New Silver Compounds as Wound Healing Material Problems and Opportunities
			1398	Wang	The treatment of patients with multi-drug resistant cavitary pulmonary tuberculosis with gelatin containing anti-tuberculosis medicines by fiberbronchoscope
			527	Iodice	Reduction of surgical infection in pediatric cardiac surgery

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Ehrlich History, Reviews and Future perspectives on Ehrlich's Research Fields	45	Van der Zeijst	Passive Immunization for the Protection of our Global Society against Emerging Infections
			420	Warhurst	The legacy of Paul Ehrlich to antimalarial chemotherapy.
			1279	Wyatt	Two vaccines too far: the polio vaccine fiascos of 1935
			736	Graevskaya	Mast cell today
Sa	09:30	Anti-infectives - Approaches to combat resistance	1278	Kollberg	IgY (Immunglobuline from egg-Yolk) - a "magic bullet" to fight antibiotic resistance.
			356	Schwarz	Transferable Resistance to Five Different Classes of Protein Biosynthesis Inhibitors Including Oxazolidinones Mediated by the Gene cfr in Staphylococci
			1240	Mollazadeh Moghaddam	Trans-Cinnamaldehyde from Cinnamomum zeylanicum Bark Essential Oil Reduces the Clindamycin Resistance of Clostridium difficile In Vitro
Sa	09:30	HPLC, capillary electrophoresis, and other analytical techniques	1133	Huang	Application of Electrochemical Analysis to the Determination of (A), Trace Amounts Minoxidil in Hamster Skin Follicles and (B), Residual Hydrogen Peroxide Present in the Minoxidil Formulation Excipients
			34	Al-Kindy	Pharmaceutical Analysis using Sequential Injection Analysis (SIA): A review of present Applications and future possibilities
			222	Michalska	Analysis of linezolid chiral and achiral impurities by capillary electrophoresis
			968	Nagy	Amperometric biosensor development and their clinical application
			211	Thongnoanua	Angiotensin Converting Enzyme Inhibitors Determination in Plasma by Enzyme Kinetic and High-Performance Liquid Chromatography
			1257	Bartlome	Laser-based Stable Isotope Tracing in Human Breath
			568	Abd El-Aty	Introduction of supercritical fluid extraction as a new sample-preparation procedure for isolation and identification of a pharmaceutical from biological fluids: Application to disposition kinetics

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Antibacterials - Tissue penetration of anti-infectives	203	Theuretzbacher	Evaluating our Performance: Tissue Penetration Paradigm Shift
			10014	Zeitlinger	Pharmacokinetics of Macrolides and Ketolides – where is the drug and how do we measure it?
			530	Karjagin	Infection Site Concentration of Metronidazole (MTZ) and Meropenem (MER) in Patients with Septic Shock (SS)
			933	Boselli	Serum and Alveolar Concentrations of Antibiotics during the Treatment of Ventilator-Associated Pneumonia
			130	Owen	The Ocular Penetration of Antibiotics Using a Rabbit Model that Emulates Human Topical Dosing
Sa	09:30	Antibacterials - Adverse events and mechanisms of toxicity - Part II	845	Simko	The Proarrhythmic Potential of Macrolides: The Role of Interactions. A Review
			1288	Sidoroff	When Magic Bullets Cause Collateral Damage (SJS/TEN & AGEP)
			1122	Martin	Enerceuticals Mediated Activation of the Alternative Cellular Energy (ACE) Pathway in the Therapy of Infectious Diseases
Sa	09:30	Antibacterials - Discovery - Peptide antibiotics - Part II	1113	Rebuffat	Antimicrobial peptides from bacteria: towards novel magic bullet strategies?
			976	Valenti	LACTOFERRIN ACTS AGAINST INFECTION AND INFLAMMATION THROUGH ITS INFLUENCE ON SYSTEMIC IRON HOMEOSTASIS
Sa	09:30	Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part II	271	Turel	Quinolones and Metal Ions- Friends or Enemies?
Sa	09:30	Vaccines - Antiinfectives - Influenza and other viruses	756	Deem	Sculpting the Immunological Response to Dengue Fever by Polytopic Vaccination
			966	Jiang	Development of an Inactivated Rotavirus Vaccine for the Global Immunization Agenda
			891	Li	Advanced development of seasonal and pandemic influenza vaccines
			74	Safdar	Vaccination in Patients with Cancer: Strategies to Prevent Influenza and Pneumococcal Disease
			997	Oldak	High uptake of vaccines – a „magic bullet” in control the burden of hospitalisation attributable to childhood mumps and rotavirus infections.

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Vaccines - Antineoplastic - Role of immune cells - Part I	479	Van Tendeloo	RNA-modified dendritic cells as therapeutic cancer vaccines: Dressed for success ?
			1117	Heimberger	EGFRVIII-targeted vaccine (CDX-110) induces immune responses and prolongs survival when given with temozolomide in GBM patients
Sa	09:30	Antifungals - Pharmacokinetics and formulation issues	281	Fuhrmann	Pharmacokinetics of anitmycotic drugs during continuous renal replacement therapy
			367	Al-Marzouqi	Complexation of Itraconazole with Cyclodextrins for Enhanced Solubility, Dissolution and Bioavailability
Sa	09:30	Antifungals - New approaches and their success	166	Pauli	(-)-?-Bisabolol – a Specific Ergosterol Biosynthesis Inhibitor ?
			1216	Mardh	Mannose-binding lectin in the defence against genital candida infections.
			273	De Lucca	In Vitro Antifungal Synergy Between the Plant Saponin, CAY-1, and (1) Two CAY-1 Structurally Related, Inactive Saponins and (2) Silver
			1101	Ventolini	Vulvovaginal Colonization by Aspergillus Species in Nonimmunocompromised Women
Sa	09:30	Antibacterials - New mechanisms and delivery strategies - Part II	919	Becker	Gut Health-Promoting Adhesion Of Enteropathogens To Dietary Polysaccharides
			954	Jeong	Perspective of chromatin structure on Topoisomerase II: Exclusive dynamics between the nucleosome and the drug target in Saccharomyces cerevisiae
			864	Shabahang	The impact of a mixture of doxycycline, an acid and a detergent on root canal debridement
Sa	09:30	Antibacterials - Peptide antibiotics and their intricacies	10012	Tam	Antibacterials & Peptide antibiotics
			541	Daugelavicius	Polymyxin B: how this Magic Bullet kills Gram-negative Bacteria?
			447	Rangaswamy	Polymyxin B Sulphate: A Brief Overview
			613	Cotter	Magic Bullets - the Lantibiotic approach

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Antineoplastic agents - Compounds and approaches - Part II	543	Vanden Berghe	The natural NFkB/IKK2 inhibitor and steroidal withanolide Withaferin A, isolated from leaf extract of the Ayurvedic plant Withania somnifera Dunal (Ashwagandha), is a novel promising chemosensitising compound in B-cell chronic lymphocytic leukemia and metastatic breast cancer
			1171	Yazaki	Membrane transport of alkaloids and anticancer drugs in plants: specificity and analogy to mammalian cells
			1750	Reiter	Molecular pathogenesis and targeted treatment in BCR-ABL negative chronic myeloproliferative neoplasms".
Sa	09:30	Antineoplastic agents - Delivering a Magic Bullet to its target(s) - Part II	496	Avgoustakis	Targeted delivery of cisplatin using polymeric nanoparticles
			948	Kondo	pH Dependent 5-Fluorouracil Release System using Polymeric Micelles
			944	Maitani	Design of Folate-linked Liposomal Doxorubicin to its Antitumor Effect in Mice
			1684	Coester	New Applications for Micro- and Nanoscaled Drug Delivery Systems
Sa	09:30	Antineoplastic agents - New targets & compounds - Part II	651	Pandey	Targeting the vulnerability of cancer cell mitochondria to selectively induce apoptosis: Evaluating the efficacy of Pancreatistatin as a non-toxic anti-cancer agent
			1192	Costi	Small Peptides Challenge Thymidylate Synthase Dimerization and Inhibit Ovarian Cancer Cells Growth
			1120	Chandra	Novel clinically relevant proteasome inhibitors and HDAC inhibitors
Sa	09:30	Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part II	120	Hartinger	THE DEVELOPMENT OF TUMOR-INHIBITING METAL COMPLEXES: (MULTINUCLEAR) METAL COMPLEXES and MODE-OF-ACTION STUDIES
			149	Wijtmans	The Anti-Tumor Action of the Hybrid Drug Nitric Oxide-Donating Aspirin Relies on the 'Passive' Linker and not on Nitric Oxide Nor on Aspirin: An Overview of an Interesting Twist

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Treatment of asthma, COPD, and other lung diseases - Part II	1383	Seidegard	Variability of the Systemic Availability of Budesonide in Man when Administered Locally at Different Levels in the Gut with Different Doses of Ketoconazole
			1268	Varney	Cotrimoxazole an 'old magic bullet' finds a new target and benefit in Advanced fibrotic lung disease
			214	Fox	Omalizumab: the first real magic bullet for the treatment of allergic asthma?
Sa	09:30	Parkinson's disease, mechanism of disease and treatment - Part I	1605	Finberg	Rasagiline, a Selective Suicide Inhibitor of Monoamine Oxidase B, Increases Striatal Extracellular Fluid Dopamine Levels and Locomotor Stimulation Following L-dopa Without a Corresponding Increase in Dyskinetic Movements in a Parkinsonian Rat Model
			1060	Cyr	Behavioural and cellular consequences of excessive amounts of the powerful brain chemical dopamine.
			607	Fiore	PARKINSON DISEASE - PARKINSONISMS - Etiopathogenesis - Treatment
			381	Jankovic	IS LEVODOPA THE MAGIC BULLET FOR PARKINSON'S DISEASE?
Sa	09:30	Vaccines - Physiology and molecular biology - Part II	598	Alfsen	The Role of cell membrane lipid environment in antigenic peptide structure-function
			760	Amemiya	The F1-V Plague Vaccine Can Activate the Innate Immune Response Through Toll-Like Receptor2 and 4 but Does Not Need Them for an Antibody Response to the Vaccine
			445	Germeroth	Adoptive immunotherapy with Streptamer-selected HCMV specific T-cells after allogeneic stem cell transplantation
			289	Kricek	Anti-Idiotypic Vaccines Against Autologous Antigens: Designed Ankyrin Repeat Proteins as Scaffolds to Break Self Tolerance?
			849	Lü	MHC Molecules as Antigen Receptors?
			38	Pumpens	Virus-Like Particles As Magic Bullets For Immune System
			659	Tietz	Innovative Method For Quality Control of High Molecular Weight Semi-synthetic Vaccines

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Cardiovascular - Pharmacological action in the cardiovascular system from small molecules to peptides and vaccines - Part II	60	Mager	Pharmacokinetic-Pharmacodynamic Modeling of Aliskiren Effects on Biomarkers of the Renin-Angiotensin System in Humans
			1139	Sood	Targeted Pulmonary Delivery of Aerosolized PGE1: A "Magic Bullet" for Neonatal Pulmonary Hypertension?
			1351	Besikci	Trimetazidine Revisited: Current and Future Applications of Metabolic Modulation of the Heart
			1042	Assy	The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis
Sa	09:30	Anti-infectives - Reviews on Magic Bullets - Part I	920	Battelino	Ear Surgery – Place for Topical use of Mitomycin C
			658	Nelwan	Levofloxacin for typhoid fever: A Story of Unlimited Success
			350	Preziosi	Isoniazid: It Was or It Is a Magic Bullet?
Sa	09:30	Ehrlich`s research fields: Historical aspects and latest research results	104	Chakrabarty	Magic Bullets versus Shotgun Drugs in Cancer Therapy and Prevention
			1026	Gorenstein	How Did The MAGIC BULLETS Drop The Knife Out of The Surgeon's Hand.
			78	Liu	Antibiotic magic bullets: The promise and the reality of the past 30 years.
			312	Debue-Barazer	From immunity theory to anti-infectious chemotherapy. Why awarding two Nobel prizes in 1908 to Paul Ehrlich (from Germany) and Elie Metchnikoff (from France). What consequences for medical research?
			611	Masic	Globalization and influence of Nobel prize winners for medicine and physiology to development of modern medicine during 20th and 21st century
187	Robert	Receptors for Magic Bullets. Ehrlich, Precursor of Receptor-mediated Drug Action. Application to Age-related Pathologies. A Review			

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	New / known targets & mechanisms - Part II	967	Ofner III	Macromolecular Conjugates for Passive Tumor Targeting: In Vitro Studies with a Gelatin-Methotrexate Conjugate
			1018	Steele	A common molecular basis for ryanodine receptor dysfunction in malignant hyperthermia and catecholaminergic polymorphic ventricular tachycardia provides opportunities for novel therapeutic strategies
			1312	Bornancin	Control of ceramide levels by ceramide kinase: evidence from knockout animals and use of a novel potent inhibitor
			226	Chin	Dual mechanistic anorexigenic and anti-adipogenic therapeutic for the treatment of obesity
			1258	Kantele	Differential Targeting of Immune Response after Antigen Encounter at Different Mucosal Sites – a Tool For Vaccine Development
			957	Cuppoletti	Prostones as CIC-2 Channel Activators for Treatment of Diseases and Disorders.
			2	Chene	New targets for new drug discovery opportunities
Sa	09:30	Vaccines - Antineoplastic - Antigen guided	1123	Gnjatic	Antibody responses in cancer vaccines and immunotherapies: from cancer/testis antigens to new targets discovered by protein arrays
			973	Grizzi	Cancer-testis antigens: effective molecules for developing successful immunotherapeutic strategies in the light of cancer complexity
			688	La Porta	Melanoma initiating cells: new perspectives in therapy?
			632	Loskog	AdCD40L Cancer Vaccine ? From Experimental Models to Clinical Application
			763	Medin	Direct lentiviral injection induces potent anti-CEA immunity in CEA transgenic mice
			674	Minev	Designing Vaccines for Cancer: Synthetic Analogs and Nano-Delivery Approaches
			925	Kratzer	FUSION PROTEINS FOR FLEXIBLE VACCINE ANTIGEN TARGETING TO CELL SURFACE RECEPTORS
Sa	09:30	Vaccines - Antiinfectives - Bacteria, parasites, and HPV	1065	Zeng	Nasal Vaccination against Bacterial Toxins
Sa	09:30	New findings on purines	866	Jennings	P2X purinergic receptor modulation of excitatory nociceptive transmission involve NMDA receptors
			6	Landolt	Adenosine: Magic bullet against disordered sleep?
			599	Hofer	Non-selective and selective adenosine receptor agonists in the treatment of radiation- and chemotherapy-induced myelosuppression
			949	Vlajkovic	Adenosine-Based Therapies for Hearing Loss

Day	Time	Session	No.	Name	FINAL TITLE
Sa	09:30	Anti-infectives - Mechanisms of bacterial resistance - Part II	124	Oelschlaeger	A Computationally Designed Mutant of the Metallo-b-lactamase IMP-1 Exhibits Enhanced Catalytic Efficiency
			624	Linton	Dodging the bullets: an update on the multi-drug efflux pump P-glycoprotein
			1295	Wilson	Counteracting drug resistance by nutritional management and genetic improvement of disease resistance - lessons from in-silico studies for nematode infections of sheep
Sa	09:30	Treatment of tuberculosis and other infections	1004	Liu	Intrinsic antibiotic resistance mechanisms of Mycobacteria
			1058	Greenstein	The "antiinflammatory" 5-ASA, "immune-modulators" azathioprine, 6-MP, methotrexate & thalidomide and "immune-suppressants" Cyclosporine A, Rapamycin & Tacrolimus are all unsuspected "Magic Bullets" the inhibit M. avium subspecies paratuberculosis growth in culture
			1093	Yew	Fluoroquinolones in the Treatment of Tuberculosis : current status and future issues.
			379	Wallis	TNF mAbs: Magic bullets for tuberculosis?
			709	Obez	Improving treatment of urinary tract infections in elderly : roles and functions of information technologies to suggest antibiotic prescriptions and to measure their effects
			323	Mahara	Tetracyclines: a historical pitfall and additional concept on the treatment of rickettsial diseases
			1003	Kienzler	From 4 to 1 weeks of treatment down to a single-dose application: a novel topical formulation of terbinafine for dermatophytoses
Sa	12:00	Antiparasitic compounds - Molecular and genomic approaches	1308	Kagawa	Antibody based protein-function analysis on the ryanodine receptor and troponin isoforms in Caenorhabditis elegans
			748	Neveu	Levamisole Resistance in Parasitic Nematodes Investigated at the Molecular Level
			765	Hoenigsberg	A GENOMIC PARASITE IN THE EVOLUTION OF METAZOAN DEVELOPMENT
			1367	Raboudi	Control of Infective Aphids in Tunisia using Molecular Tools: Biotechnological Approach to protect Food Crops.

Day	Time	Session	No.	Name	FINAL TITLE
Sa	12:00	Atherosclerosis, stroke & aging - mechanisms and treatment - Part II	4	Hoenig	The Utility of the Cholestanol:Cholesterol Ratio in Predicting LDL-Cholesterol response to Atorvastatin 80 mg: A paradigm for individualized lipid-lowering therapy
			1473	Jeyaraj	EFFECT of FISH OIL (MEGA-3) AND GARLIC OIL (GARLIC PEARLS) SUPPLEMENTATION ON THE ANTHROPOMETRIC MEASUREMENTS, BLOOD PRESSURE AND SERUM LIPID PROFILE IN WOMEN WITH HYPERCHOLESTEROLEMIA
			456	Khavinson	Peptides against Ageing
Sa	12:00	Cardiovascular - Drugs acting on the cardiovascular system - Part III	1078	Asgeirsdottir	Targeting Dexamethasone-Loaded anti-E-selectin Liposomes Prevents Glomerulonephritis Progression: The Potential of Vascular Bed-Specific Drug Delivery
			1757	Torzewski	Generating C-reactive protein inhibitors for the treatment of cardiovascular disease
Sa	12:00	Cardiovascular - Magic Bullets & the cardiovascular system - Part I	161	Nalivaiko	Central sympatholytic and anti-arrhythmic effects of 5-HT _{1A} agonists
			483	Scheen	Rimonabant, first CB ₁ receptor antagonist, a potential magic bullet to reduce cardiometabolic risk in patients with abdominal obesity
			262	Weitz-Schmidt	Beyond cholesterol lowering: Immunomodulatory effects of lovastatin
			745	Brooks	Novel targets and magic bullets for treating cardiovascular disease
			655	Ventura	Hyaluronan Mixed Esters of Butyric and Retinoic Acids: Multicomponent-Multitarget Drugs with Differentiating and Paracrine Logics for Cardiovascular Repair with Human Mesenchymal Stem Cells
			373	Kragten	Nifedipine, the most cited, studied, experienced and debated Ca-antagonist: where has it gone?
Sa	12:00	Vaccines - History, Reviews, and Future Perspectives - Part I	904	Rundblad	Dissemination and Communication: Selling Vaccines to Peers and the General Public
			1221	Harandi	Vaccine Adjuvants for Sexually Transmitted Infections: Recent Developments and Future Challenges
			1168	HORIUCHI	The success story of Japanese DTaP control and a further development of vaccine evaluation
			1050	Fujii	The VesiVax® System: Vaccinology's Magic Bullet?
			206	Rath	The Vienna Vaccine Safety Initiative (ViVI) – an International Scientific Forum aiming to Promote Evidence-based Vaccine Safety Research and Communication

Day	Time	Session	No.	Name	FINAL TITLE
Sa	12:00	Antibacterials - Unexpected findings and new approaches	850	Tanzer	Xylitol Resistance of Streptococcus mutans Appears To Be An Unexpected Benefit to The Human Or Rodent Host
			1239	Dudeja	Pathophysiology of Enteropathogenic E. coli-induced diarrhea: Potential Therapeutic Role of Probiotics
			1549	Majeed	Competitive interactions in Escherichia coli populations: the role of Bacteriocins
			869	Nagata	Stimulation of Proline Uptake and Growth of Escherichia coli CSH4 and its Mutants under High Salinity through Moderate Salinity Stress Treatment
			723	Sekimizu	Silkworm infection models to evaluate the therapeutic effects of antibiotics
Sa	12:00	Antibacterials - New antibiotic and antineoplastic compounds from nature - Part II	803	Prabha	Sperm immobilization factor: potential candidate for fertility control and antibacterial targeting bacterial motility
			839	Sperandio	Inter-kingdom cell-to-cell inhibitors: a novel target for antimicrobial drugs.
			1174	Sockett	Predatory Bdellovibrio bacteria as living antibiotics:- Nature's Magic Bullets to treat antibiotic-resistant Gram-negative infections.
			1287	Itsko	A Series of Antibacterial Toxins Made from Inactive Cyt-Like ORF of Bacillus thuringiensis subsp. israelensis Using The Microgene Polymerization Reaction
			1155	Leung	Exploring Anti-microbial Herbs of Chinese Medicine.
363	Curkovic Perica	Auxins: effects on bacteria and tumours			
Sa	12:00	Antineoplastic agents - Balancing efficacy and toxicity	1465	Hiyama	Effectiveness and complications of treatment for childhood liver tumors – from the experience of JPLT (Japanese Study Group for Pediatric Liver Tumor) study
			916	Bayram	Light (LM) and electron microscope (EM) examination of the effects of methotrexate (MTX) on the endosalpinx.
			278	Pereira	Adverse reactions of titanium-based chemotherapeutic agents on male reproductive organs
			1034	Sato	Possible role for human leukocyte antigen haplotypes in hepatotoxicity and/or pancreotoxicity associated with chemotherapy
			1343	Hu	Novel Targeted Anticancer Prodrugs of Phosphoramidate Mustard

Day	Time	Session	No.	Name	FINAL TITLE
Sa	12:00	Resistance - a Global Issue for diverse therapeutic areas - Part I	208	Erenpreisa	Cancer cell life-cycle: The mechanism of genotoxic resistance.
			622	Gomes	Molecular Imaging of Multidrug Resistance Mediated by ABC Transporters in Osteosarcoma
			1169	IONESCU	Insulin resistance: between myth and reality
			720	Tucker	Mechanism of Resistance in Non Hodgkin's Lymphoma- Expression of Fas Ligand on Endothelial Cells Lining Blood Vessels
			852	Deckers	Battling pharmacoresistance in epilepsy patients: pharmacodynamic and pharmacokinetic approaches
			504	Dharmasaroja	Aspirin Non-responders in Thai Ischemic Stroke/TIA Patients
Sa	12:00	Vaccines - Antiinfectives - HIV - Part II	833	Hioe	Using immune complexes to enhance antigenicity and immunogenicity of a neutralizing epitope on HIV-1 envelope gp120
			1224	Tarasenko	Bait bullets controlling Bacillus anthracis: from spore inhibition to toxins neutralization and prevention of spore- and/or toxin-induced cell death.
			1399	Vyas	Synthesis of a Novel Subunit Vaccine against HIV-1: Native Envelope Proteins in Lipid Bilayer of Inactivated Virions Devoid of p24, RT and Viral Nucleic Acids
			490	Bouzianas	Current Medical Countermeasures (Vaccines- Antibodies- Antibiotics) to Protect Humans from the Anthrax Bioterrorism
			1779	Harrer	Interactions between the HIV-specific Immune Response and the Development of Resistance to Antiretroviral Drugs.
Sa	12:00	Vaccines - Development, production and manufacturing - Part II	1395	Ouerfelli	Complex Carbohydrate-Based Cancer Vaccines: Magic Bullets in the Making?
			1013	Smith	Finding a New Vaccine in a Ricin Protein Fold
			906	Arcangeli	Single-Chain Antibodies and Immunoconjugates: Computational and Functional approaches
			566	Mansour	Enhanced depot vaccine formulations, VacciMax and DepoVax, for cancer and pandemic influenza applications

Day	Time	Session	No.	Name	FINAL TITLE
Sa	12:00	Antidepressant drugs and their mechanism of action - Part II	191	D'Aquila	Dopamine transmission and the search for the ideal antidepressant drug
			33	Smith	Magic Bullets for PET Brain Imaging of Antidepressants in Man
			1187	Schlech	Ocular Infections: Impact of Resistance to Fluoroquinolones and Other Antibiotics on Topical Therapies
			853	Plachouras	Emergence of colistin resistance during therapy of infections by multi-drug resistant gram negative pathogens in the critically ill
Sa	12:00	Antineoplastic agents - New targets & compounds - Part II	692	Pines	Targeting the Tumor Microenvironment as a Modality to Combat Cancer – Effect of Halofuginone
			629	Flescher	Jasmonates Kill Cancer Cells Selectively by Dissociating Hexokinase from Mitochondrial VDAC
			316	Treiber	mTOR Inhibitors for Hepatocellular Cancer (HCC) - A moving Target -
			1052	Osaki	MicroRNA as a novel drug for cancer metastasis: Suppression of lung metastasis of osteosarcoma in in vivo model
Sa	12:00	Antineoplastic agents - Personalized therapy - Part II	777	Cücer	Prognostic value of total AgNOR area/Nucleus area per cell in urinary bladder carcinoma via two-dimensional image analysis
			727	Lee	COXEN: A New Strategy for Predicting the Chemosensitivity of Human Cancers and its Application to Drug Discovery
			419	Trost Jorgensen	Personalized Medicine - a Paradigm Shift in the Treatment of Cancer
Sa	12:00	Antivirals - New compounds and their mechanisms - Part I	800	Ohru	Development of Highly Anti-HIV Active and Lowly Toxic 4'-C-Ethynyl-2'-deoxy-2-fluoroadenosine and A Proposal of The Way to Develop Highly Active and Lowly Toxic Antiviral Modified Nucleosides
			1103	Sinko	Targeting HIV Reservoir & Sanctuary Sites Using Peptide Backbone Polyethylene Glycol (PEG) Nanocarriers
			1151	Lori	Virostatics: a new class of immunomodulators (leading compound in Phase II) with dual antiviral and cytostatic properties to inhibit viruses and protect the immune system from hyperactivation during chronic infections
			890	Ragno	Identification of Novel Hepatitis C Virus Polymerase NS5B Inhibitors Through Structure-Based Virtual Screening and 3-D QSAR Studies

Day	Time	Session	No.	Name	FINAL TITLE
Sa	12:00	Drug transporters and delivery - Part II	1206	Ohtsuki	Reconstruction of In Vivo P-Glycoprotein Activity from In Vitro Information by Targeted Absolute Proteomics
			1262	Almqvist	Molecular Dynamics Simulations of human membrane transport proteins from the Major Facilitator Superfamily.
			274	Israeli	Hypothesis on the physiological significance of the expression of the drug transporters <i>mdr1</i> and <i>Abcg2</i> during normal tissue regeneration and after cancer therapy
			311	Grdisa	Delivery of specific targeted drugs into the cells by TAT-technology
Sa	12:00	Antineoplastic agents - Search and Development of new Magic Bullets - Part I	653	Aoki	A potential tumor cell-penetrating peptide, CRGD ₂ CF(K[H]-J ₃ KK) ₆ , for the delivery of antisense and siRNA oligonucleotides
			1172	Caraglia	Molecular strategies to improve the anti-tumour activity of Zoledronic acid in prostate cancer cells
			174	Noteborn	Apoptin magics: bullet or sensor?
			940	Raucher	Thermally Targeted Delivery of Anticancer Peptides by Elastin-like Polypeptide
Sa	12:00	Vaccines - Antiinfectives - Bacteria and parasites - Part II	687	Oster	APPLIED REVERSE VACCINOLOGY: A MENINGOCOCCAL SEROGROUP B VACCINE FOR INFANTS
Sa	12:00	Vaccines - Targeting non-infectious diseases - Part II	426	Crameri	Allergy vaccines: dreams and reality
Sa	12:00	Steroids, Receptors & pulmonary diseases	830	Johnson	Seretide:a revolution in the treatment of asthma and COPD
			1012	Michalides	Predicting optimal endocrine treatment for hormone-dependent breast cancer through the right bullets and targets
			70	Barker	Allosteric modulation of hormone receptors in cancer treatment
			1234	Frye	Estrogen Receptor Beta may be a Novel Target for the Beneficial Effects of Estrogens in Females, and Androgens in Males, for Anxiety, Depression, and Cognitive Function
			896	Nagasaki	Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer
998	Prakash	Cell-specific delivery of kinase inhibitors using lysozyme: A novel approach to treat renal fibrosis			

Day	Time	Session	No.	Name	FINAL TITLE
Sa	12:00	Brain physiology, biochemistry, and drugs acting on the brain - Part II	1062	Szot	Treating the Untreatable: Alpha 1-Adrenoreceptor Antagonist Prazosin for PTSD, Disruptive Agitation in AD and Alcohol Dependence.
			1124	Hashimoto	PACAP signaling: a promising drug target for neuropsychological disorders
			1051	Uehara	A novel view of the pathophysiology of psychiatric disorders and development of pharmacotherapy based on brain energy metabolism
			578	Simola	How Prolonged Exposure to Caffeine Can Affect Dopaminergic Transmission: Evidence from Rats Subchronically Treated with Caffeine and Possible Implications
Sa	12:00	Antibacterials - PK/PD: past, presence, and future challenges	10011	Schentag	PK/PD in patients - Learning from our Failures
			349	Goessens	Changing the dosing frequency of ceftazidime transforms this "Daisy cutter" into an antibiotic with limited collateral damage while retaining its efficacy
			10007	Neely	Pharmacometric Tools to Optimize Modeling and Control of Drug Therapy for Patient Care
				Wilke	Decoding infections - How to use „administrative“ data for clinical quality improvement
Sa	13:00	Targets, Drugs and Carriers – Approaches to Translational Medicine Financial support: German Research Foundation (FG463)	1688	Kleuser Dernedde	Sphingosin 1-phosphate signalling and therapeutic implications Multivalency as action principle for the suppression of inflammatory processes
				Danker Korting	Glycosidic Phospholipids: Inhibitors of cell proliferation and migration Inhibitors of secreted aspartic proteinases for the treatment and prevention of candidoses
				Dathe Schäfer-Korting	Targeting of blood vessels by small ApoE-like peptides From fundamental research in carrier-related skin penetration to polymerase-alpha inhibitors for skin tumor therapy

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part II	815	Norrby	UNEXPECTED EFFECTS ON ANGIOGENESIS BY TYPE OF LOW-MOLECULAR-WEIGHT HEPARIN AND BY TYPE OF VEHICLE IN CHEMOTHERAPY
			762	Yang	Interfere IGF-I pathways to augment sensitivities of colorectal cancer cells to current therapeutic agents
			874	Matsumoto	Inhibition of Tumor Metastasis and Angiogenesis by NK4, Bifunctional Inhibitor of HGF-Met and Angiogenesis.
			729	Taspinar	CYP1A1, GST Gene Polymorphisms and Risk of Chronic Myeloid Leukaemia
			291	Gunes	The effects of cytochrome P450 enzyme polymorphisms on bladder cancer and prostate cancer
			169	Atanasoski	Distinct cell cycle proteins control Schwann cell proliferation in health and disease
			42	Markopoulos	The Role of Heat Shock Proteins in Oral Cancer: A Possible New Target in Antineoplastic Therapy?
Sa	14:00	Treatment of diseases with involvement of the immune system - Part III	981	Slos	Cancer Immunotherapy with Adenovirus-IFN γ (TG1042).
			268	Fuchs	Role of antiproliferative enzyme indoleamine (2,3)-dioxygenase in the impaired immune function in infectious diseases
			626	Prohic	Novel biologic therapies for psoriasis
			1132	Nydegger	INTRAVENOUS IMMUNOGLOBULIN THERAPY TARGETING MULTIPLE BULLET HOLES.
			1199	Nicolini	Hormone-immunotherapy significantly prolongs clinical benefit and median overall survival of metastatic endocrine dependent breast cancer patients
Sa	14:00	Immunosuppressants - Part II	402	Jovanovic	Is Cyclosporine the magic bullet in dermatology?
			340	Riccardina	Efficacy of 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood
			29	Thervet	Nephrotoxicity of immunosuppressive drugs : New insights

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Antineoplastic agents - New strategies and new compounds- Part II	10000	Vavanasi	[Title will be available soon]
			298	Badria	Antineoplaston: Synthesis, Biology, and Clinical Evaluation in Egypt
			1325	Michl	New Anti-Cancer Peptides that Cause Lysis and Necrosis of Tumor Cells but Have No Effect on Normal Cells
			744	Messori	Anticancer gold compounds: mechanistic insights
Sa	14:00	Antineoplastic agents - Compounds and approaches - Part III	592	FitzGerald	Recombinant Immunotoxins for the Treatment of Cancer
			481	Borsig	Heparin as an inhibitor of cancer progression; the role of selectins
			82	Carlson	Vascular disruption: an old mechanism rediscovered for targeting tumor blood supply
			1328	Hatina	Cancer stem cells - towards a new generation of antineoplastic drugs
			353	Bago-Horvath	Synergistic Action of Resveratrol and its Polyhydroxylated Derivative with Cytarabine in HL-60 Human Promyelocytic Leukemia Cells
Sa	14:00	Vaccines - Development, production and manufacturing - Part III	205	Kalbe	Adjuvant Systems for Vaccines Targeting Unmet Needs: From Concept To Clinical Evidence.
			589	Milstien	Challenges and potential solutions to innovative vaccine development in developing countries
			701	Van Regenmortel	Antibody polyreactivity and ill-defined levels of antigen mimicry hamper the search for effective peptide-based vaccine immunogens
			105	Stantic Pavlinic	RABIES IN BATS AND PROTECTIVE TREATMENTS OF HUMANS IN EUROPE
Sa	14:00	Mechanisms of inflammation and anti-inflammatory agents - Part II	1164	Szolcsanyi	Advent of pharmacology of nociceptors initiated by capsaicin has opened also a new world in neurohumoral regulation
			1173	Hartog	Orally Ingested Lactoferrin and Glycine Display in vivo Synergistic Anti-Inflammatory Activity
			1277	Dandona	INSULIN SUPPRESSES HIGH MOBILITY GROUP-B1 (HMG-B1) PROTEIN AND TOLL LIKE RECEPTOR EXPRESSION: FURTHER EVIDENCE OF ITS ANTI-INFLAMMATORY EFFECT

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Antineoplastic agents - Creating Magic Bullets from natural compounds - Part I	1069	Alauddin	Trabectedin: A new anticancer bullet from the sea
			1059	GAGO	Trabectedin: a new bullet from the sea
			158	Jung	Discovery & Development of Antineoplastic Magic Bullets from Natural Products
			654	Patel	Retinoic acid regulates the expression of the anti-apoptotic protein PKCdeltaVIII.
			563	El-Mowafy	Chemopreventive and cellular protective effects of Resveratrol and EGCG in human and animal cancer models.
			1481	Caceres	The differential dose-dependence for pro-angiogenic and cytotoxic effects of new anticancer plant agent within different nanocarrier formulations.
			1232	Elvin-Lewis	Magic Bullets from Ethnobotanical Sources: Challenges and Concerns
Sa	14:00	Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part II	1137	Chadha	ANTI-ANGIOGENIC AND ANTI-NEOPLASTIC POTENTIAL OF PROSTATE-SPECIFIC ANTIGEN
			495	Iamaroon	Oral cancer: molecular pathogenesis and novel therapeutic approach
			1220	Mallucci	Targeting cancer through PI3K by the bGBP cytokine and induction of apoptosis by the activation of alternative pathways.
			1135	Backer	Is GRP78/BiP, a Master-Regulator of Defensive Unfolded Protein Response, a New "Magic Target"? GRP78/BiP-targeting Cytotoxin and ER Stress-Inducing Drugs Synergize to Kill Cancer Cells
			520	Celie	Heparin as anti-inflammatory and anti-metastatic drug- new potentials of an old player
Sa	14:00	Antineoplastic agents - Old and new compounds / approaches - Part I	453	Merkel	Arsenic Trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavorable prognostic factors including del17p13
			294	Samoylova	Phage Display: Opportunities for Development of Personalized Anti-Cancer Therapeutics
			672	Tai	Chemotherapeutic agents for Merkel cell carcinoma - past, present and future
			1519	Muller	Cell Penetrating Antibody Delivery to Intracellular Targets

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Antiparasitic compounds - Magic Bullets to treat malaria	1041	Gosling	Sulfadoxine- Pyrimethamine: Dead or alive for malaria control?
			1350	Saliba	Vitamin utilisation pathways as antimalarial drug targets
			1385	Tasic	Structure and Antimalarial Activity of Immunomodulator P-MAPA
			1079	Dardonville	Bis(2-aminoimidazolium)diphenyl Compounds as DNA Minor Groove Binders with in Vivo Antitrypanosomal and Antimalarial Activity: the cation is important
Sa	14:00	Pharmaceutics - Drug delivery - Part III	12	Wang	On the Delivery of Carmustine, Paclitaxel, and Etanidazole to Brain Tumors: An integrated study on the novel fabrication methods of pharmaceutical particles and 3-D computer simulations for chemotherapy and radiotherapy applications
			333	Vijaya Raghavan	Study of Tenoxicam on Various Drug Delivery Systems
			820	Babu	Transdermal Drug Delivery into and beneath the skin - Application to Analgesics and Anti Inflammatory Drugs
Sa	14:00	Antivirals - Mechanisms and development of antivirals - Part II	190	Desideri	Synthesis, Anti-rhinovirus Activity and Mechanism of Action of New Chromene and Chroman Derivatives
			1073	Huang	Combinational therapeutics Targeting Laboratory and Clinical Isolates of HIV-1
			711	Biswas	Epidemiology of Highly Pathogenic Avian Influenza Outbreaks in Bangladesh
Sa	14:00	Nerve diseases, mechanisms, and pathophysiology - Part II	618	Macchi	Antiviral chemotherapy in HTLV-1 infection: Highlights from in vitro studies
			928	Salkovic-Petrisic	Glucose Transporter Type 2 - Does It Pave the Way to Sporadic Alzheimer's Disease?
			1114	Zolotov	Proline specific peptidases as a new targets for drug development. Pharmacology and Pathophysiology
			886	Dash	The Role of PPAR gamma Agonist in Alzheimer's disease

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Drug-drug and drug-nutrient interactions - Part I	137	Liebovitch	Advantages of Multiple Drug Interactions: Combinatorial Treatments Using Neural Networks
			485	Popescu	Pharmacokinetic and pharmacodynamic interactions between mepivacaine and antihypertensive drugs
			1270	Endringer	Natural products from plants and its derivatives as CYP19 (aromatase) inhibitors: flavonoids and dihydroisocoumarin
			582	Katende-Kyenda	Factors that influence the prevalence of drug-drug interactions between antiretroviral drugs in a healthcare sector in South Africa
			1353	Mahgoub	Let food be thy medicine and medicine be thy food
Sa	14:00	Bioanalytics - The cutting edge of LC-MS/MS - Part II	10000	Sauber	Microfluidics-driven HPLC-Chip / Triple Quadrupole Mass spectrometry - shattering the sensitivity barrier for small animal pharmacokinetic studies
			440	Chen	iTRAQ-coupled 2D LC-MS/MS Analysis of Proteomics Profile in Cells Incubated with S- or R-enantiomers of Chiral Drugs: from Metabolic Pathways to Biomarker Discovery
			133	Hsieh	The Role of Metabolism, Pharmacokinetics and Mass Spectrometry in Selection of a Thrombin Receptor Antagonist for Development
			507	Nordström	LC-MS/(MS) strategies for increased metabolite coverage in metabolomics
			215	Soltermann	LC-MS/MS shotgun proteomics of lung cancer pleural effusions identifies the prognostically relevant epithelial-mesenchymal transition protein periostin
Sa	14:00	Pharmaceutics - Drug delivery - Part II	1250	Jones	Bioconjugated Cytotoxin Prodrugs and Imaging Agents in Anticancer Research
			1160	Thomas	Magnetic Resonance Imaging 'Pathfinder' Molecules For Use in Optimizing Antibody and Gene-Directed Enzyme-Prodrug Therapy (ADEPT/GDEPT) Treatments
			923	Nieddu	Corpora non agunt nisi fixata: tailored drug targeting by intelligent active principles or intelligent transporters, state of art and our experience
			1340	Sremac	Recombinant Gas Vesicles: A Novel Display/Delivery System For Peptide Antigens (SIV)
			176	Paleos	Targeted and Multifunctional Dendritic Polymers: Magic Bullets for Drug and Gene Delivery

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Therapeutic Proteins - discovery and manufacturing - Part II	397	Hefferon	Biopharmaceuticals in Plants; Toward the Next Century of Medicine
			960	Maines	The Critical Functions of Biliverdin Reductase (BVR) in Insulin/Insulin Growth Factor-1 (IGF-1) and MAPK Signaling Pathways: A Potential Therapeutic Application in Treatment of Diabetes and Cancer
			487	Sugiura	Recombinant therapeutic proteins - - from the viewpoint of a biotechnologist
			1196	Engström	Spider silk proteins - the next generation of bioimplantable materials. Biochemical structure and mechanical function
Sa	14:00	Antibacterials - The rise of antibacterial resistance	695	Aminov	Antibiotic resistance: what we can learn from evolution?
			988	Van	Molecular Characterization of Antibiotic Resistance in Selected Enteropathogens Isolated from Raw Food Samples in Vietnam
			861	Inai	Pathophysiological Approach against Resistant Bacteria-causing Infectious Diseases; - from Autopsy Findings to Clinical Applications
			1393	Ayling	Antimicrobial Resistance by Mycoplasma species in Farm Animals.
			471	Saberi	National Surveillance of Antibiotic Resistance in Iran
			1776	Kaier	The impact of antimicrobial drug use and the use of alcohol-based hand rub on the emergence and spread of extended-spectrum β -lactamase (ESBL)-producing strains - A time series analysis
Sa	14:00	Blood brain barrier physiology and diseases - Part II	716	Krizbai	Molecular Changes Induced by Stress Factors in Cerebral Endothelial Cells
			49	Raghavan	Breaching the Barriers of the Brain: from physics to cures
			623	Kozler	Effects of Intracarotid Injection of Methylprednisolone on Cellular Oedema after Osmotic Opening of the Blood-Brain Barrier in Rats
			577	Kraus	The impact of interferon- γ treatment on the blood-brain barrier

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Antineoplastic agents - Approaches to optimize therapy - Part II	10006	Jaehde	Optimizing therapy by platinum compounds via PK/PD
			347	Rocchetti	Predicting the active doses of new anticancer agents in humans directly from preclinical data
			53	Chow	Nanomedicines - Self Nanoemulsifying Drug Delivery System (SNEDDS) and Nanosuspension for Oral and Parenteral Formulations in Cancer Therapy with Significant Impacts on Pharmacokinetics and Biodistributions
			1127	Watanabe	Targeted Therapy of Human Neuroblastoma Cells using Auger Electrons of Indium-111-labeled N-myc Antisense Oligonucleotide
			220	Steinbach	Which ABC-transporters should we target in leukemia?
			1107	Fan	Synergistic or Antagonistic Interaction between Taxanes and G1/S Arresting Agents in Combination Therapy
			774	Dreves	Personalized anticancer therapy – impact of biomarkers
835	Banerjee	Search for a novel biomarker for the malignant brain tumor Glioblastoma Multiforme			
Sa	14:00	Psychoactive drugs - Part I	740	Monassier	Ketanserin and dexfenfluramine: angels or demons for serotonergic 5-HT ₂ receptors ?
			265	Pinault	PSYCHOTOMIMETIC ACTION OF KETAMINE AND MK-801: BEHAVIORAL, NETWORK AND CELLULAR FEATURES
			306	Wu	Feasibility of Mapping Brain pH Using 31P MR Spectroscopy
			1454	Nulman	Neurodevelopment of Children Following Exposure to Psychotropic Medications During Gestation: a Novel Approach to Behavioral Teratology
			1142	Salminen	Nicotinic acetylcholine receptor containing an alpha6 subunit: target for a magic bullet?
			1357	Shaw	Substance Use and Its Functions, Dysfunctions, and Alternative Functions in Contemporary Society
			978	Zelena	Neuropeptides in Stress-Related Disorders: Possible Interaction of Vasopressin and Corticotropin Releasing Hormone
			1774	Kirchheiner	Pharmacogenetic diagnostics for optimization of psychotropic drug treatment

Day	Time	Session	No.	Name	FINAL TITLE
Sa	14:00	Erythropoietin - a Magic Bullet's quovadis	111	Krzyzanski	Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin
			389	Gilmartin	Erythropoietic Stimulating Proteins - What is the Optimal, Safe Hemoglobin Target?
			69	Lappin	Erythropoietin in Cancer Anaemia: Friend or Foe?
			474	Lee	Erythropoietin-binding protein and Its Antibodies For Possible Clinical Application
			560	Maiese	ERYTHROPOIETIN: BOLD DIRECTIONS AND STRATEGIES FOR A MAGIC BULLET DESTINED FOR NEUROVASCULAR DISEASE
			317	Park	Erythropoiesis-stimulating agents may improve survival in low-risk MDS patients
Sa	14:00	Antivirals - General issues and their solutions - Part II	529	Hellden	Aciclovir- a nearly atoxic antiviral drug with severe neurotoxic side effects. A retrospective review of 280 cases and the importance of analysing the aciclovir metabolite CMMG
			84	Urosevic	Principal parallels between Interferon type I- and small inhibitory (si)RNA- based therapies
			15	Roca	Present knowledge on pharmacogenetics of antiretrovirals ROCA B
			1335	Kedhar	The impact of highly active antiretroviral therapy on cytomegalovirus retinitis: triumphs and future challenges
			209	Amarapurkar	Clinical importance of drug resistance in antiviral therapy for Hepatitis B Infection
			1019	Smith	Rapid intervention: the role of antivirals in containing or controlling pandemic influenza
Sa	16:45	Nerve diseases, mechanisms, and pathophysiology - Part III	733	Mancuso	Bilirubin: an Endogenous Molecule with Antiviral Activity in vitro
			195	Ohadi	A Novel Polymorphic Purine Complex at the 1.5 kb Upstream Region of the Human Caveolin-1 Gene and Risk of Alzheimer's Disease; Extra-Short Alleles and Accumulated Allele Homozygosity
			72	Seidl	Neurotoxicity Related to Lithium Combination Treatment in a Patient with Schizoaffective Disorder
			612	Shad	Drug cell interaction at molecular level
			539	Bartels	Blood-brain barrier P-glycoprotein function in aging and neurological disease: in vivo measurements in humans with [11C]-verapamil PET
			836	Penkowa	Innovative nanopharmaceutical strategies for neuronal survival and regeneration after traumatic brain injury

Day	Time	Session	No.	Name	FINAL TITLE
Sa	16:45	Antineoplastic agents - Clinical trials and approaches- Part II	667	Shimada	Treatment strategies for multiple liver metastases from colorectal cancer
			1184	Muir	Teaching an old dog new tricks: Intralesional Bleomycin Injection (IBI) Treatment of Vascular Birthmarks
			277	Maisch	Intrapericardial Cisplatin Treatment Prevents Effectively the Recurrence of Neoplastic Pericardial Effusion.
			1755	Reichle	Systems-directed targeted therapies in metastatic tumors: Equitable to reductionist therapy approaches?
			1474	Semczuk	Correlation between clinicoprognostical features and allelic loss at TP53 in metastatic endometrial cancer
Sa	16:45	Antineoplastic agents - Effectiveness and resistance in patients - Part III	1056	Haluska	The insulin-like growth factor pathway- the key to overcoming resistance in cancer therapy?
Sa	16:45	Antineoplastic agents - Biochemical approaches	742	Dabrowska	Methotrexate induces permanent growth arrest in human adenocarcinoma cells.
			877	Hiratake	"Rational design of specific inhibitors of g-glutamyl transpeptidase (GGT) and g-glutamylcysteine synthetase (GCS) for modulating cellular glutathione and redox status"
			693	Mizutani	Mechanism of Oxidative DNA Damage and Apoptosis Induced by Doxorubicin through Generation of Reactive Oxygen Species
			990	Mycielska	Citrate transport mechanism in prostate and its changes in malignant transformation. Implications for fatty acid synthesis in cancer
			1296	Smetana	The cytostatic treatment effect on nucleoli of leukaemia cells at the single cell level
Sa	16:45	Antineoplastic agents - Tyrosine Kinase Inhibitors - Part II	512	Wcislo	EARLY RESULTS OF IMATINIB AS THE ACTIVE AGENT IN CONTROL OF AGGRESSIVE FIBROMATOSIS. An Attempt of Metaanalysis.
			145	Razi	Lapatinib: New Expectations
			766	Papadimitriou	Receptor protein tyrosine phosphatase beta/zeta as a possible new target to regulate endothelial and tumour cell migration
			198	Pricl	In vitro hypothesis, in vivo veritas. Success and failure of Imatinib in cancer target therapy

Day	Time	Session	No.	Name	FINAL TITLE
Sa	16:45	Treatment of severe infections including sepsis	10015	Joukhadar	What we have learned in recent years in the therapy of life threatening Staphylococcus aureus infections!
			412	Bondar	Current systemic and local therapies of intra-abdominal sepsis
			1368	Mezey	Bone marrow stromal cells attenuate sepsis and sepsis-induced acute kidney injury (AKI) via a novel mechanism of action.
			950	Yermak	New anti-endotoxins agents againts gram-negative bacteria infections
Sa	16:45	Steroid receptor - Jensen symposium	1185	Purohit	Steroid Sulfatase Inhibitors – Novel Therapeutic Agents for Hormone Dependent Cancers
			386	Schoenlein	A Role for Macroautophagy in Antiestrogen Resistance
			1202	Bhavnani	Mechanisms that Explain the Lower Incidence of Breast Cancer in Postmenopausal Women Treated with Conjugated Estrogens (CEE). Role of Estrogen Receptor a and b.
			559	Chapman	Competing Causes of Death from a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer: NCIC CTG MA.17
			1361	Khripach	New Steroidal Hormones Promise to Become a Multi-Purpose "Magic Bullet"
Sa	16:45	Therapy with monoclonal antibodies - Part I	394	Pathan	Lumiliximab, a novel therapeutic agent for the treatment of Chronic Lymphocytic Leukemia (CLL)
			518	Montalban	First-line treatment with Rituximab combined with intravenous or oral Fludarabine for patients with extranodal Mucosa Associated Lymphoid Tissue (MALT) lymphoma.
			899	Ohsugi	Blockade of IL-6 signalling with a humanized anti-IL-6 receptor antibody, tocilizumab, for the treatment of rheumatoid arthritis
			596	Stebbing	New Medicines, New Problems: Understanding the failure of the phase I clinical trial of monoclonal antibody TGN1412
			245	Scali	Infliximab: Beyond the primary expectatives
Sa	16:45	Cytochrome P450 drug metabolism	10000	Unger	New Substrates for the Major Drug Metabolising Cytochrome P450 Enzymes
			185	Terziivanov	Application of population pharmacokinetic analysis and Monte Carlo simulations method in drug phenotyping. Assessment of cytochrome P450 1A2 activity in a population of adult non-related Caucasians from sparse data
			1273	Luedtke	The gut, the forgotten metabolic organ: the story of testosterone and dextromethorphan
			1371	Johnson	Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: Therapeutic relevance

Day	Time	Session	No.	Name	FINAL TITLE
Sa	16:45	Anti-infectives - PK/PD modeling strategies and applications	10005	Forrest	Mechanistic PK/PD modeling of anti-infectives - what does this approach have to offer?
			283	Schuck	PK/PD Modeling of Time-Kill Curves: Addressing Biphasic Killing Patterns
			10000	Bulitta	A new paradigm for modeling the time-course of antibacterial combinations
			551	Noreddin	Predicting Fluoroquinolones ability to kill resistant Streptococcus pneumoniae isolates expressing different genetic mutations: Clinical simulation of several treatment and mutation scenarios
			1043	Raugei	Computational investigation of infectious disease mechanisms: from HIV-1 virus inhibition to bacterial resistance to antibiotics
1553	Nguyen	In vitro pharmacodynamic evaluation of intracellular activity of antibiotics (ABs) alone or in combination against a small colony variant (SCV) of Staphylococcus aureus			
Sa	16:45	Antiparasitic compounds - Leishmaniasis and its intricacies	1027	De Vries	The Pharmacokinetics and Pharmacodynamics of Miltefosine for Leishmaniasis.
			1307	Dorlo	The Role of ABC Transporters in the Pharmacokinetics of Miltefosine for Leishmaniasis
			1366	Emadi	New Strategic treatment for cutaneous leishmaniasis by local injection Glucantime + triamcinolone 1/20ratio) in 250 patient in Bam-Iran
			1321	Idris	Antiplasmodial and Immunomodulating Activity of Some Sudanese Herbal Medicine with emphasis on Pristimerin as Antiplasmodial and Antileishmanial Agent
			1046	Ghaffarifar	Photodynamic therapy as a new method for the treatment of cutaneous leishmaniasis
Sa	16:45	Antivirals - New compounds and their mechanisms - Part II	1283	Geiben Lynn	Development of Serpin drugs for the treatment of HIV/HCV co-infections
			749	Bell	Synthesis and QSAR studies of CADA analogs with CD4 down-modulating and anti-HIV activities
			750	Ho	System approach to Magic Bullets: tissue and cell targeted delivery of HIV and cancer drugs
			951	Lukyanov	Anti-HIV activity of lectins from marine invertebrates

Day	Time	Session	No.	Name	FINAL TITLE
Sa	16:45	Sex steroids	66	Wallner	Chronic Levonorgestrel Treatment in a Macaque Species (<i>Macaca sylvanus</i>): effects on sex steroids and secondary sex characteristics
			737	Van Veen	A functional steroid-binding element in an ATP-binding cassette multidrug transporter
			1108	Piasek	Metals as endocrine disruptors in women's reproduction: assessment of effect and mechanism of action in different steroidogenic cells
			40	Carruthers	Biting the Magic Bullet of Testosterone Treatment: Why Androgen Resistance Causes Problems in the Diagnosis of Androgen Deficiency.
			177	Szulc	Role of estradiol and testosterone in the regulation of bone metabolism in men and women
Sa	16:45	Parkinson's disease, mechanism of disease and treatment - Part II	51	Magyar	Four decades in selegiline research; historical aspects, further perspectives
			1354	Szende	Anti-apoptotic and apoptotic action of (-)-deprenyl (Selegiline) and its metabolites
			782	Aschner	Manganese (Mn) Transport at the Blood-Brain Barrier: Implications for Parkinson's-Like Disease
			292	Pokorski	N-Oleoyl-Dopamine: A Potential Novel Deliverer of Dopamine to the Brain
Sa	16:45	Pharmaceutics - Nanoparticles and their latest developments - Part II	1604	Mueller	Investigations into sulfur nanoparticles as drug carriers
			1259	Bhogal	Nanodevices for targeted delivery: An evaluation of toxicological models
			917	Harakeh	Polyethylene Glycol Gold Coated Nanoparticles for the Enhancement of the Efficacy of a Specific Nutrient Synergy
			887	Morein	One bullet, two targets! A nano-particle with two key medical applications

Day	Time	Session	No.	Name	FINAL TITLE
Sa	16:45	Resistance - a Global Issue for diverse therapeutic areas - Part II	1084	Dei	N,N-bis(alkanol)amine aryl esters and N,N-bis(cyclohexanol)amine aryl esters: identification of a new class of Pgp-dependent multidrug resistance (MDR) reverters endowed with potencies in the nanomolar range
			524	Pasquini	Central glutamatergic dysfunction as an explanation of resistance and refractoriness in Obsessive-Compulsive Disorder.
			767	Tatischeff	And what if we used for therapeutic drug delivery, the magic bullets that Dictyostelium discoideum cells expel as a multidrug resistance mechanism?
			764	Cox	Aspirin resistance myth or reality?
			307	Stordal	The Inverse relationship between Cisplatin and paclitaxel resistance: Two 'magic bullets' are needed
			549	Wang	Role of Efflux Drug Transporters in Drug Resistance
Sa	16:45	Therapeutic Proteins - clinical studies - Part II	404	Biermasz	Treatment outcome and management of acromegaly before and after the introduction of somatostatin analogs
			74	Safdar	GM-CSF in SCT Recipients: Response to Early vs Late Serious Infections
			8	Makinoda	A New Application of Granulocyte Colony-Stimulating Factor (G-CSF) in the Female Reproductive Medicine
			538	Michalska	Recombinant factor VIIa (rFVIIa) for the treatment of bleeding in abdominal surgery and cardiac surgery.
			371	Smajilagic	PHARMACOKINETICS AND BIOLOGICAL EFFECTS OF THE RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-7 IN VIVO
Sa	16:45	Vaccines - Antiinfectives - Herpes	832	Awasthi	Preventing Immune Evasion as a Strategy for Enhancing the Effectiveness of Herpes Simplex Virus Vaccine
			794	Rajcani	The herpes simplex virus (HSV) vaccines: old problems, new challenges
			1379	Arico	Vaccination with Recombinant MHV68 Producing IFN α Effectively Protects Mice Against Infection With Wild Type MHV-68 and Dramatically Reduces the Establishment of Long-term Spleen Latency.

Day	Time	Session	No.	Name	FINAL TITLE
Sa	16:45	Antibacterials - PK/PD of antibiotics in serious infections	1642	Mouton	[Title to be finalized.]
			10008	Jelliffe	NEW PROTOCOLS FOR INSTITUTING CONTINUOUS INTRAVENOUS VANCOMYCIN THERAPY
			425	Roberts	Piperacillin dosing in ICU - what are the magic bullets?
			912	Peterson	High-dose Levofloxacin to Reduce Duration of Therapy and Slow Emergence of Resistance
			348	Aubert	Value of pharmacokinetic/pharmacodynamic in dose management of ceftazidime and imipenem in ICUs
Sa	16:45	Antiparasitic compounds - Discovery	477	Akue	In vitro Activities of Extracts from Natural Plants on the Human Filaria Loa loa
			842	Duschak	Sulfated oligosaccharides as main targets in cruzipain, the major cysteine proteinase of Trypanosoma cruzi
			604	Hudecz	Drug-Peptide Conjugates with Antitumour or Anti Parasite Activity
			1484	Paquet	A Novel, Safe, and Effective Clinical Treatment to Eliminate Resistance in Ectoparasites
Sa	16:45	Antineoplastic agents - Genomic approaches to optimize therapy - Part I	359	Adachi	Generation of Human Gene Knockout Cell Lines: Application to Assessment of Genotoxic Anticancer Drugs
			364	Gong	Development of prognostic and predictive variables in breast cancer: personalized approach using gene expression profiling microarray
			1227	Khalkhali-Ellis	Treatment Prospects for Breast Cancer: Lessons Learnt from a Decade of Research on Maspin
Su	08:45	Antibacterials - Clinical Aspects - Part III	141	Maharaj	Antibiotics at Cesarean section- Is it a must?
			171	Saxena	Optimizing outcomes of hemodialysis catheter-related infections through intraluminal Cefotaxime - heparin lock placement.
			755	Kozlovsky	Chlorhexidine Gluconate - Local Antimicrobial Agent in Aid of Prevention and Treatment of Periodontal and Peri-implant Diseases
			570	Vavilin	The prognostic value of genetic and phenotypic markers of drug metabolism and host and exposure factors for antituberculous drug induced hepatotoxicity

Day	Time	Session	No.	Name	FINAL TITLE
Su	08:45	Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part III	75	Perez-Stable	INCREASED EXPRESSION OF TUMOR-SPECIFIC CYCLIN B1 SENSITIZES PROSTATE CANCER CELLS TO APOPTOSIS INDUCED BY ANTI-MITOTIC DRUGS
			256	Weiger	Antiproliferative Properties of Quinidine
			107	Veinberg	Unprecedented antitumor effect of irradiation generated by 5-trimethylsilyl-2-trifluoroacetyl-furan oxime in fibrosarcoma cells
Su	08:45	Antineoplastic agents - Metal-based compounds to combat cancer	1230	Sun	Some Uses of Metal-Based Complexes as Anti-Tumor Agents
			754	Matsui	Global and local structure of cisplatin and DNA base pair complex: a theoretical study
			17	Deubel	Platinum and Non-Pt Anticancer Drugs: Insights from High-Level Computations
			677	Berube	Development of unique cisplatin analogs for site-specific treatment of hormone-dependent female cancers
			922	Lukawska	AMIDINOANTHRACYCLINES - PERSPECTIVES TO PROMISING MODIFICATION OF KNOWN ANTICANCER DRUGS
			10	Mishra	Ruthenium complex in Cancer Therapy: In vitro and in vivo studies
Su	08:45	Antineoplastic agents - New strategies and new compounds- Part III	670	Matteson	Innovations in organoboron chemistry essential to the discovery of bortezomib
			467	Banik	Synthesis and Biological Evaluation of Anticancer β -Lactams
			683	Queiroz	Synthesis of fluorescent heteroaromatic compounds using dehydroamino acids as building blocks, studies of DNA and biomembranes interactions. Evaluation of antiproliferative effects on tumor cell lines
			606	Kasyanenko	DNA Conformation in Complexes with Coordination Compounds
			872	Wang	Temozolomide Acid Hexyl Ester (TMZA-HE) as a Topical Bullet for Skin and Cervical Cancers

Day	Time	Session	No.	Name	FINAL TITLE
Su	08:45	Antineoplastic agents - Combination therapy to optimize effectiveness	953	Tsuchiya	Revolutionary impacts of caffeine-potentiated chemotherapy on osteosarcoma treatment
			1207	Haveman	Combination with hyperthermia and radiation contributes to the magic of cisplatin in cancer treatment.
			457	Denham	Magical interactions between cisplatin, fluorouracil and radiation benefit oesophageal cancer patients
			1251	Jamison	Apatone®, a Combination of Vitamins, with In Vitro, In Vivo and Clinical Effectiveness against Prostate Cancer
			779	Tsunoda	?Phase ? study of S-? combined with irinotecan (CPT-??) in patients with advanced colorectal cancer?
Su	08:45	Antineoplastic agents - Compounds and approaches - Part IV	1006	Bloch	Therapeutic Differentiation of Insulinoma Cell Lines Treated with Streptozotocin
			189	Gilloteaux	A new mode of cell death for tumor cells after ascorbate : menadione treatment in vitro and in vivo
			545	Banerjee	A NOVEL ANTI-ANGIOGENIC GLYCOTHERAPEUTIC FOR BREAST CANCER
			424	Sathornsumetee	Firing the "Magic Bullets" at Brain Tumors: From Bench-to-Bedside and Back Again
			1327	Kestler	ODAM as a Diagnostic and Therapeutic Target for Human Breast Cancer
1753	Malek	Argyriin A a new type of proteasome inhibitor with potent anti-proliferative and anti-angiogenic activities.			
Su	08:45	Brain physiology, biochemistry, and drugs acting on the brain - Part I	587	Lampson	Learning from the brain: Attacking targets in the brain / what the brain can teach us about other organs
			971	Jaubert	A New Physiological Role for Dopamine and its Transporter in the Pituitary: Induction of Prolactin Cells Apoptosis at Weaning
			1198	Park	Glial Cell Line-derived Neurotrophic Factor Family Artemin-Transcriptional Regulation, Neurite Outgrowth and Actin Polymerization in Mature Dorsal Root Ganglia Neurons.
			584	Meshitsuka	Gene expression in brain and kidney in response to aluminum in drugs
			668	Suzuki	Chemical chaperone therapy: magic bullet to the brain in GM1-ggngliosidosis

Day	Time	Session	No.	Name	FINAL TITLE
Su	08:45	Drug-drug and drug-nutrient interactions - Part II	1508	Ajaime Azzalis	EFFECTS OF ALCOHOL AND SUCROSE INTAKE ON RAT LIVER CYP2E1
			534	Astrand	How to avoid drug—drug interactions
			675	Bailey	Are Grapefruit, Orange, Lime, Pummelo and Apple the Forbidden Fruits of Drug Interactions?
			301	Goldstein	Frovatriptan - the triptan with the least drug/drug interactions
Su	08:45	Therapeutic Drug Monitoring, Personalized Medicine, and immunosuppressive agents	230	Akhlaghi	Effect of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics of Immunosuppressive agents: Ciclosporin, Tacrolimus and Mycophenolic Acid
			10013	Vinks	Applications of Pharmacometrics to Immunosuppressive Therapy in Transplant Patients: Can we do better?
			700	Hassan	Therapeutic drug monitoring in Malaysia: an overview after two decades of practice
Su	08:45	Metabolic Diseases	506	Ching	A potential molecular link for metabolic stress and carcinogenesis: AMP-activated protein kinase
			757	Lugnier	Specific Inhibitors of the Cyclic Nucleotide Phosphodiesterases PDE2 and PDE4 Overcome In Vitro and In Vivo Angiogenesis
			263	Harant	Selective inhibition of signal peptide-dependent cotranslational translocation by the cyclopeptolide CAM741
			1404	Iglic	Suppression of Membrane Microvesiculation – a Possible Anticoagulant and Anti-Tumor Progression Effect of Heparin
			93	Gupta	Protection to whole body and other severely damaged cellular entities in mice pretreated with a combination of signature molecules isolated from Podophyllum hexandrum and exposed to whole body lethal radiation
Su	08:45	Bioanalytics - The cutting edge of LC-MS/MS - Part III	332	Yin	Pharmacokinetic and drug metabolism, a bioanalytical perspective
			501	Pal	HPLC and MALDI TOF MS analysis of novel antileishmanial compounds from Quassia amara
			1653	Boos	A generic, multidimensional SPE-platform for undisturbed LC-MS/MS analysis of basic drugs in native biofluids
			1654	Morello	A unique SPE-LC-MS/MS platform for fully automated analysis of drugs in native whole blood
			1194	Wang	Assessing the Metabolic Liabilities of Aromatic Amines Using In Vitro Metabolism and Mass Spectral Techniques

Day	Time	Session	No.	Name	FINAL TITLE
Su	08:45	Analgesia & analgetic drugs III	136	Mavromoustakos	A concerted approach using Physical Chemical Methodologies, Computational Chemistry and 3D QSAR Studies aiming to develop novel Analgesic cannabinoid analogs.
			14	Großherr	Infusion monitoring of anesthetic drugs: propofol in respiratory gas
			666	Wiley	Targeted cytotoxins in neuroscience: Magic Bullets for pain research and treatment
Su	08:45	Pharmaceutics - Experimental and computational approaches - Part III	135	Rauch	Interfacing cell's membrane and drugs' mechanical properties to control bioavailability: application to Lipinski's 2nd rule and resistance to drugs
			657	Latypov	Temperature, Denaturant and Ligand Effects on Solution Stability and Conformational Properties of Human Interleukin-1 Receptor Antagonist
			790	Fernandes dos Santos	Structure-Activity Relationships of Some 1,4-Dihydropyridine (DHP) Derivatives Evaluated by Interactions with the Physical Properties of Synthetic Lipid Bilayers and Rat Liver Mitochondrial Bioenergetics
Su	08:45	Illicit drugs & similar agents, doping and performance enhancement drugs	1324	Grabherr	Radiological detection of dissolved cocaine by Computed Tomography
			565	Rousseaux	Cannabis and Cannabinoids: the forgotten magic bullet?
			650	King	Opioid Agonist or Opioid Antagonist: Magic Bullets in the Treatment of Opioid Addiction
			484	Vandenbergh	The role of the dopamine transporter gene in smoking and other addictive behaviors
			398	Pinna	Anabolic Androgenic Steroids (AAS) Elicit Aggression by Selectively Decreasing Neurosteroid Biosynthesis in Corticolimbic Glutamatergic Neurons

Day	Time	Session	No.	Name	FINAL TITLE
Su	08:45	Psychoactive drugs - Part II	811	Prolo	Cellular Immune Toxicity of Alcohol and Cocaine: Medical Practice Based on the Evidence vs. Evidence-Based Medical Practice
			1000	Popova	The Role of the Genotype in the MAGIC BULLET Effect of Psychotropic Drugs
			160	Yamada	In Vivo Analysis of Brain Muscarinic Receptor (mAChR) Occupancy by Anticholinergic Agents Analyzed via Quantitative Autoradiography (ARG) and Positron Emission Tomography (PET)
			868	Soza Ried	The effects of lithium on vestibular activity are related to mood states in bipolar disease
			515	Omura	Nicotine dramatically increases impulsive behavior. –can nicotinic acetylcholine receptor antagonist suppress impulsive behavior?-
			738 934	Papadopoulos van Os	Neurosteroids in the treatment of neurodegeneration Differences in plasma levels of risperidone: causes and consequences
Su	08:45	Therapeutic Proteins - discovery and manufacturing - Part III	1134	Chen	From Mono- to Dimeric-IRFs: The Heart of the Matter in Activation of the Interferon Regulatory Factors
			180	Uriarte	Inhibition of Neutrophil Granule Exocytosis by a Novel Cell-Penetrating SNAP23 Fusion Protein: A Potential Magic Bullet?
			840	Konaklieva	Serine Protease Inhibitors: Cross Inhibitors of Procaryotic and Eucaryotic Systems
			1145	Mariani	Prospective, structured data collection for recombinant FVIIa: the STER experience on 55 surgical interventions in patients with congenital FVII deficiency
			1097	Wang	Therapeutic protein engineering via the incorporation of non?natural amino acids
Su	08:45	Vaccines - Antiinfectives - Bacteria, parasites, and HPV	636	Stiles	Staphylococcal Enterotoxin Vaccines: Future Utility for Fighting Staphylococcus aureus?
			908	Horii	The clinical pipeline of A candidate malaria vaccine that targets the Achilles' heelantigen of Plasmodium falciparum
			1099	Donders	Change in Knowledge of Women about Cervix Cancer, Human Papilloma Virus (HPV) and HPV Vaccination due to Introduction of HPV Vaccines
			1126	Onodera	Developement of a novel DNA vaccine targeting macrophage migration inhibitory factor and its efficacy on murine models of inflammatory diseases

Day	Time	Session	No.	Name	FINAL TITLE
Su	08:45	CNS - Pharmacological options in disease of the central nervous system - Part IV	1223	Abdulrazik	Non-Systemic Delivery of Ocular Brimonidine to the Brain: Extending the Therapeutic Benefits of Brimonidine to the CNS
			1554	Yip	Inhibitory balance of gamma-aminobutyric acid in cerebellar circuitry in autism: a circuit-centered approach to drug target design for developmental neurobiological disorders
			697	Jabbi	Experienced Life Stress and Genetic variations of MAOA, COMT, 5-HTT and 5-HTT 2nd_Intron Mediates Behavioral and Endocrine Stress Responses
			639	Kasteleijn- Nolst Trenité	Valproate (VPA): unrecognized value from an old molecule
			793	Nonogaki	Serotonin bridge of 5-HT2C - 5-HT1B receptor over appetite
			553	Prokai	Application of Prodrug Strategies to Create Magic Bullets for the Treatment of CNS Maladies
Su	08:45	Treatment of asthma, COPD, and other lung diseases - Part III	1075	Kim	Tumor Necrosis Factor (TNF)-a Inhibitors Effectively Treat Asthma
			671	Hochhaus	Inhaled glucocorticoids: Are they a magic bullet for treatment of asthma and COPD?
			1807	Högger	Explaining pulmonary pharmacokinetics of inhaled corticosteroids: how close to in vivo reality can we get?
			1055	Azuma	EM703 a New Derivative of Erythromycin, Inhibits Lung Fibrosis Induced by TGF-b Signaling in Murine and Human Lung Fibroblasts
			1260	Marcus	Anti IgE Therapy in the management of Asthma: Present use and possible future applications
Su	11:15	Analgesia & analgetic drugs IV	556	Ariza	Remifentanyl: Its impact on human and earthly pain and new perspectives
			399	Ray	Acetaminophen: The Global Pain Killing Magic Bullet of the New Millenium
			1214	Lewis	Development of Novel c-Conopeptide Inhibitors of the Norepinephrine Transporter for the Treatment of Severe Pain
			376	Aram	Preoperative use of analgesia in appendicitis

Day	Time	Session	No.	Name	FINAL TITLE
Su	11:15	Antibacterials - Discovery - Peptide antibiotics - Part III	505	Anastasiadou	Production, isolation, partial characterization and antimicrobial spectrum of a novel bacteriocin produced by a <i>Lactobacillus plantarum</i> strain in fermentation
			609	Zamyatnin	STRUCTURAL AND FUNCTIONAL DIVERSITY OF ENDOGENOUS ANTIMICROBIAL OLIGOPEPTIDES
			228	Franco	Are the tropical forests the new frontier for antibiotics discovery? Novel peptidomics insights on the screening of plant antimicrobial peptides
			97	Papagianni	Isolation, purification, partial characterization, biochemical properties and stability of two novel antimicrobial peptides produced by <i>Pediococcus</i> strains.
Su	11:15	Anti-infectives - Reviews on Magic Bullets - Part II	943	Nicholson	Doripenem, a new carbapenem: optimizing dose to treat increasingly resistant Gram-negative pathogens.
			1697	Trautmann	Use of Pharmacodynamic Modeling to Predict Efficacy of Doripenem, a Class 2 Carbapenem recently Licensed in Europe
			415	Straus	Daptomycin: Old drugs, New data, Endless Puzzles.
			873	Inagi	Organ protective effects of tunicamycin as an endoplasmic reticulum stress inducer
			649	Babalola	Significant Drug-Drug interactions between classical antibiotics and antimalarial drugs
Su	11:15	Antineoplastic agents - Clinical trials and approaches- Part III	814	Takakura	Interferon gene therapy against metastatic cancer
			335	Lambert	Magic Bullets: Beyond Selective Targeting to Selective Killing Using Armed Antibodies
			303	Beumer	New approaches for the use of old drugs - preclinical and clinical pharmacological evaluation of the pyrimidine anti-neoplastics: zebularine, 5-fluoro-2'-deoxycytidine, gemcitabine, 5-fluorouracil, and THU
			1228	Corey	Is there a magic bullet for prostate cancer bone metastases?
Su	11:15	Antineoplastic agents - Effectiveness and resistance in patients - Part IV	489	Nath	Optimising High Dose Melphalan in patients with Multiple Myeloma: Preliminary results from a multi-centre trial
			56	Newton	Longterm Therapy of Brain Tumors With Temozolomide: Review of Tolerability and Efficacy in 53 Patients
			1253	Mazur	Amifostine (WR-2721) as a cytoprotective aminothiols agent
			1064	Lin	Hyaluronan-Mediated Transformation and Relapse of Prostate Cancer

Day	Time	Session	No.	Name	FINAL TITLE
Su	11:15	Therapy with monoclonal antibodies - Part II	380	Seo	In Vivo Molecular Imaging of Capromab Pendetide in Humans and Small Animals Using Combined Dual-Modality SPECT/CT and microSPECT/CT Systems
			1639	Kloft	Monoclonal antibodies: potent therapeutic proteins - not only in cancer treatment
			962	Gosselin	Monoclonal Antibodies as Vaccine Adjuvants: From Potential to Protection
			411	Skubitz	Potential use of denosumab in the treatment of giant cell tumor of bone
			423	Lopez	Intracavitary-administered Nimotuzumab labeled with 188Re in adult recurrent high-grade glioma
Su	11:15	Antineoplastic agents - New mechanisms & compounds - Part III	894	Santos	New potential dual drugs for targeting specific MMPs and CAs involved in cancer
			1166	Mohamed	ROLE OF ULTRASOUND WAVES IN ENHANCING THE EFFECT OF ANTICANCER DRUG.
			1049	Pistoia	IL-12 receptor expression and function on human lung adenocarcinoma: identification of a new potential therapeutic target
			1070	Gariepy	Combinatorial Ribosome-Inactivating Protein Libraries: Part of a New Arsenal in Combating Cancer
			134	Baguley	The action of a new drug that targets a cancer's blood supply: the story of DMXAA (ASA404)
			1229	Lu	A New Molecular Mechanism of Action of a Leading Chemotherapeutic Drug—Cisplatin and Its Novel Applications
			1373	Wang	Nucleotide excision repair (NER) in cisplatin-induced cellular responses
			865	Roberts	Enhancing radiotherapy of cancer using agents that target thrombospondin-1 and CD47

Day	Time	Session	No.	Name	FINAL TITLE
Su	11:15	Biomarkers & personalized medicine	1382	Helgason	Matching the Individual Patient to the Results of Large Clinical Trials and Testing the Null Hypothesis Using Fuzzy Theory
			374	Pradeep	Exploring Leukotriene B4 (LTB4) as a periodontal biomarker: A time to focus.
			472	Van Dyke	Pharmacogenetic screening and drug susceptibility to fetal malformations, past, present, and future
			680	Smith-Sonneborn	Activation of Ancient Stress-resistance Pathways by Molecular Triggers, Age and Disease Intervention
			989	Masuo	Integrated 'OMIC' analyses of the rat brain: Novel biomarker candidates for mental disorders and stress
			255	Atmeh	Small Lipoprotein A-I subclasses (42,000-70,000) are Promising Biomarkers in Cardiovascular Disease
			1760	Pachmann	Circulating epithelial tumor cells (CETC) allow gene analysis of the residual tumor burden individual chemosensitivity testing and monitoring of the adjuvant setting in a curative
			1506	Lisowska-Myjak	Alpha-1-antitrypsin and IgA in Serial Meconium and Faeces for Date Newborn's Faeces Formed during Intrauterine and Extrauterine Maturation.
Su	11:15	Cardiovascular - Drugs acting on the cardiovascular system - Part IV	344	Vavlukis	Can Cardiovascular Drugs Influence Clinical outcome in CABG patients
			773	Vesely	Cardiac Hormones: Magic Bullets for the Treatment of Congestive Heart Failure, Renal Failure and Cancer
			454	Baudin-Creuz	Cell-free octameric hemoglobin as a blood substitute
			129	Benga	WATER CHANNEL PROTEINS (AQUAPORINS): FROM THEIR DISCOVERY IN 1985 IN CLUJ-NAPOCA, ROMANIA (BY THE USE OF A DOPING NMR METHOD AND SPECIFIC LABELING) TO THE USE OF THEIR INHIBITORS AS MAGIC BULLETS
			900	Takahiro	Serum hepcidin level (HEPC) is a significant predictor of arterial stiffness in maintenance hemodialysis patients (mHD).
			544	Iakoubova	Genetic variant of KIF6 predicts both increased risk for coronary events and greater benefit from statin therapy: an overview of genetic studies of the CARE, WOSCOPS, and PROVE IT - TIMI 22 trials

Day	Time	Session	No.	Name	FINAL TITLE
Su	11:15	New / known targets & mechanisms - Part I	1677	Heaysman	Chemoembolisation Using Drug Eluting Beads: Magic Bullets Targeted by Arterial Guidance.
			681	Fernandes	Blocking the Peptide Tunnel- Is the Magic Still There?
			436	Cheung	From Gene Expression Profile to Identification of Molecular
			952	Katunuma	Structure Based Development of Selective Inhibitors for Individual Cathepsins and Their Medical Applications for Therapeutic purposes
			99	Benedek	The Path from Colles' Law to the "Magic Bullet.
Su	11:15	Resistance - a Global Issue for diverse therapeutic areas - Part III	153	Lounsbury	Proposed antiangiogenic agents with mechanisms that prevent tumor cell survival and resistance to cytotoxic therapies
			689	Spigelman	THE UNCERTAIN FUTURE OR THE END OF MODERN MEDICINE?: A CLINICIANS VIEW OF ANTIBIOTIC RESISTANCE-WAY TO PREVENT THE INEVITABLE
			87	Goncharova	NO-DONORS AS MODULATORS OF ANTITUMOR DRUGS RESISTANCE
			1025	Nabekura	Overcoming multidrug resistance in human cancer cells by dietary phytochemicals
			400	Molnar	Resistance as new challenge of chemotherapy for bacteria and cancer cells
Su	11:15	Treatment of diseases with involvement of the immune system - Part IV	1387	Xue	Targeted immunotherapy of cancer through TCR gene transfer
Su	11:15	Recent progress and development in nanotechnology	414	Tamanoi	Targeted Delivery of Magic Bullets by the Use of Mechanized Nanoparticles
			188	Mohapatra	Targeted Therapeutics: From Magic Bullets to Multifunctional Nanoparticles
			824	Arbabi	Recent developments of Nanomedicine in Iran
			812	Bhasakran	Preparation and evaluation of Diltiazem Hydrochloride loaded nanocapsules: Influence of various polymers
Su	11:15	Antibacterials - Adverse events and mechanisms of toxicity - Part III	656	Palermo	Potential Reproductive and Developmental Damage Induced by Metronidazole
			164	Slapsyte	Chromosome Damage in Peripheral Lymphocytes of Children with Urinary Tract Infection after Antimicrobial Therapy with Nitroheterocyclic Compounds

Day	Time	Session	No.	Name	FINAL TITLE
Su	11:15	Antibacterials - Genomic strategies	635	Good	Antibacterial RNA silencing
			1432	Ilina	Molecular investigation of drug resistant Neisseria gonorrhoeae clinical isolates
			1614	Shibayama	Screening Phage Genomes to Identify Novel Antimicrobial Targets in Mycobacteria and Related Organisms
			1377	Nishiuchi	An Arabidopsis transcription factor, AtNFXL1 gene negatively regulates Fusarium phytotoxin trichothecene-induced defense response.
Su	11:15	Antibacterials - New antibiotic and antineoplastic compounds	1098	Shaaban	Essramycin: A First Triazolopyrimidine Antibiotic Isolated from Nature
			1281	Wang	Modifying cytoplasmic protein complexome involved in energy metabolism as a strategy of Escherichia coli against ceftriaxone
			1356	Mishra	Chemistry of nitrogen and sulphur based compounds : An approach towards the discovery of magic bullets
Su	11:15	Antineoplastic agents - Genomic approaches to optimize therapy - Part II	575	Lucas	TGF-beta: A primary tumor suppressor gene involved in leukemogenesis.
			768	Chieffi	PATZ1 gene has a critical role in the spermatogenesis and testicular tumors
			468	Attarzadeh	Investigation of SGK-1 and Dexras1 expression in Human Embryonic Kidney (HEK 293) cells
			741	Mollaoglu	Expression of MAGE-A12 in oral squamous cell carcinoma
Su	11:15	Antineoplastic agents - New promising mechanisms - Part II	1261	Barsoum	Elesclomol: A Novel Oxidative Stress Inducer for the Treatment of Metastatic Melanoma
			1048	Sorokina	Betulonic acid and its alanine amide derivatives - a new multy-target agents for tumor chemotherapy
Su	11:15	Antineoplastic agents - Old and new compounds / approaches - Part II	146	Saif	BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor
			385	Wetzler	Arsenic Trioxide - teaching an old drug new tricks

Day	Time	Session	No.	Name	FINAL TITLE
Su	11:15	Antineoplastic agents - Paclitaxel - a true Magic Bullet	1005	Yusa	Incorporation of Paclitaxel into Well-Defined Amphiphilic Block Copolymer Micelle Having Phospholipid Polymer Sequence
			85	Ojima	Taxane-Based Tumor-Targeting Anticancer Agents
			787	Pizzocaro	"Germ cell tumours, squamous cell carcinoma, urothelioma: Taxanes magic bullet in urologic cancers?"
Su	11:15	Antineoplastic agents - Search and Development of new Magic Bullets - Part II	46	Su	Induction of Complete Tumor Remission by DNA-Directed Alkylating Agents
			1410	Chen	Synergistic inhibition of chemotherapy refractory primary ovarian cancer cells by oridonin and wogonin.
			590	Lewis	Molecular Targeting of the bcl-2 Oncogene for Staging and Therapy of B-Cell Lymphoma
Su	11:15	Drug-drug and drug-nutrient interactions - Part III	469	Fawcett	Neuromuscular blocking drugs and magnesium interactions
			119	Corona	ANTI-HIV AND ANTI-CANCER DRUG-DRUG INTERACTIONS
			848	Medhi	Effect of commonly prescribe NSAIDs, Protom Pump Inhibitor and Newer Anti-malarial compound on pharmacokinetics of different antiepileptics
Su	11:15	Atherosclerosis and stroke - mechanisms and treatment	856	Bayrakci	Rifampin: A Potential Life-saving Drug in Intoxication Cases
			1023	Higuchi	A new focus on atherosclerosis treatment: transialidase from Trypanosoma cruzi as an anti-proliferative drug.
			1370	Adams	Nicotinamide Mechanisms of Neuroprotection in Stroke
			309	Luoma	Cytochrome P450 and Gene-activating Agents – Cholesterol Elimination and Regression of Atherosclerosis
			94	Mohammad	Multiple Pharmacologic Approach to atherosclerosis
			95	Hadi	Multiple Pharmacologic Approach to atherosclerosis
			937	Reynolds	Neonatal Abstinence Syndrome And Cerebral Infarction Following Maternal Codeine Use During Pregnancy
101	Bustamante	Pro-atherogenic and pro-inflammatory alterations in mononuclear cells populations induced by oxidized LDL and high glucose levels in type 2 diabetic patients. Anti-inflammatory drugs, an alternative?			

Day	Time	Session	No.	Name	FINAL TITLE
Su	11:15	Pharmaceutics - Pharmacokinetics and drug formulations - Part II	637	Wesolowski	Fractal structures and body scaling of Tc-99m DTPA elimination as a function of weight and volume of distribution
			546	Reed	Divalproex-valproate: Is the discovery, research & development with this molecule and its' formulations complete?
			533	Voskresensky	The Single Structure – Activity Relationships (SAR) System and Directed Creation of New Drugs
			183 648	Menger Bijlsma	New Developments in Drug Solubilization Mannitol, a key probe molecule in the assessment of small intestinal permeability?
Su	14:15	Blood-brain barrier - History and most recent finding - Part III	712	Mikov	Bile acid derivatives as BBB modifiers
			1300	Masaichi-Chang-il	Biomedical Application of Electron Spin Resonance (ESR) Spectroscopy using Blood-Brain-Barrier permeable Nitroxyl Spin Probe.
Su	14:15	Cardiovascular - Magic Bullets & the cardiovascular system - Part II	210	Abraimi	Xenon: a magic bullet for the treatment of acute ischemia?
			218 914	Ker Sisakyan	The ACE-inhibitor: Magic bullet from myocardium to endothelium Evolution and perspectives of chronic heart failure therapy from pathophysiologic basis
			731	Alvarez Gregori	Verapamil Reverts Acute Renal Functional Impairment Induced by Angiotensin II Converting Enzyme Inhibitors
			Su	14:15	Cytochrome P450 - in vitro studies - Part II
562	McGiff	Eicosanoids: The Endless Parade: Enter the Cytochrome P450 System, EETs and HETEs			
1061	Terner	Activated iron(IV)-oxo structures in intermediates of heme enzymes and their models			

Day	Time	Session	No.	Name	FINAL TITLE
Su	14:15	Anti-infective Magic Bullets	547	Hsieh	TARGETING CLEC5A/MDL-1 FOR THE TREATMENT OF DENGUE HEMORRHAGIC FEVER
			1089	Pawlowski	Discovery and use of the magic bullets in human taeniosis/cysticercosis (niclosamide, praziquantel)
			1157	White Welte	Transfer factors - Magic Bullets for preventing and treating viruses and mycobacteria in the 21st century CAPNET - The German approach of attacking a serious infection problem
Su	14:15	Pharmaceutics - Nanoparticles and their latest developments - Part III	1106	Kamiya	A Preparation of NI-Lipid Nanoparticles by Combination of Roll Mill and High Pressure Homogenization, and Stabilization of the Nanoparticles by Gel Solidification Method -- Aiming at preparation methods of the nanoparticle without using organic solvent--
			1121	Taylor	Magic Bullets Made Easily Using Nano-particulate Membrane Bioreactors
Su	14:15	Resistance - a Global Issue for diverse therapeutic areas - Part IV	1630	Lebedev	Hydrophilic hexapeptides – a new class of ATF – dependent transport proteins of multiple drug resistance
			1386	Colpaert	Inverse Resistance: Bringing About the Inverse of Opiate Actions, 5-HT1A Receptor Activation Causes an Analgesia that Grows rather than Decays.
			244	Lei	Effect of hypoxia-inducible factor-1a silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide
Su	14:15	Vaccines - History, Reviews, and Future Perspectives - Part II	1276	Shulman	Vaccine-derived polioviruses (VDPVs) - a grey cloud around a magic bullet
			561	Nara	Immune Refocusing Technology- Improving on Mother Nature's immunogenicity
			1178	Thalen	Whooping cough vaccines: a public health and producer's perspective
Su	14:15	Therapeutic Proteins - discovery and manufacturing - Part IV	1154	Simuth	Multifunctionality of Native and Recombined Proteins of Honeybee Royal Jelly: Assumptions for Application in Pharmacy
			32	Akamizu	Clinical Applications of Ghrelin

Day	Time	Session	No.	Name	FINAL TITLE
Su	14:15	Transporters of physiological compounds and drugs - Part II	235	Gross	Acetazolamide Inhibits Electrogenic Sodium Bicarbonate Flux through kNBC1. Molecular Mechanisms and Computer Simulations.
			1304	Takara	Interaction Between Local Anesthetics, Specially Articaine, and the Sarcoplasmic Reticulum Ca ²⁺ -Adenosine Triphosphatase.
			116	Sobolev	Novel Modular Nanotransporters which Significantly Enhance Efficacy of Transported Drugs and Impart Cell Specificity to Them
Su	14:15	Vaccines - Antineoplastic - Role of immune cells - Part II	1238	Hodge	T-cells as Magic Bullets: Recombinant Vaccine Strategies for Cancer Immunotherapy
			314	Kircheis	Anti-carbohydrate specific immune response and tumor cell lysis correlate with vaccination-induced systemic release of stimulatory cytokines
			73	Neelapu	Therapeutic Vaccination for Lymphomas: Challenges and Opportunities
Fr	to So	Group of miscellaneous topics (to be assigned to symposia)	286	Kitamura	The effect of some endogenous substances (Cl ⁻ , oleate and Ca ²⁺) on the albumin binding of triflupromazine (TFZ), trifluoperazine (TFPZ) and bendroflumethiazide (BFZ). An in vitro spectrometric study
			791	Silva	Application of the fluorescence quenching method to the study of the interaction of the anti-psychotic drug Chlorpromazine with Serum Albumin
			644	Grisbolaki	[Title not yet available]
			844	Chaldakov	ADIOPHARMACOLOGY: A NEW WAY TO SEARCH FOR MAGIC BULLETS
			1365	Li	Antibody-therapeutic targeting of TolC for growth-combating of antibiotic-resistant Escherichia coli
			855	Iida	The impact of non-fucosylated therapeutic antibodies in humans in vivo
			238	Saleh	A Promising Future for Cancer Immunotherapy in an Oil-Rich Country like Kuwait: An Invitation for Pharmaceutical and Non-Pharmaceutical International Collaboration
			1071	Lin	Peripheral administration of TrkB agonists enhance appetite and weight in non-human primates
			1777	Hippe	Consequences to morphology of primary neurons as an effect of Nitric Oxide on plasma membrane fluidity
			1769	Zeilinger	Ion channels as biomolecular drug targets
			1285	Gill	Serotonin Transporter: Mechanisms of regulation by enteropathogenic E coli (EPEC)
			1710	Landersdorfer	[Title to be finalized.]